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ABSTRACT 
Many carboxylic-acid-containing drugs cause liver injury in humans. Examples include fenclozic 
acid (FA), which was withdrawn due to jaundice observed in clinical trials, and diclofenac (DFC) 
which remains widely prescribed despite being associated with liver damage. To explore 
whether these toxicities could be due to metabolic bioactivation mediated by cytochrome 
P450 (CYP) or conjugative enzymes, covalent binding (CVB) assays were done using liver 
microsomal incubations from wild-type and hepatic cytochrome P450 reductase null (HRN™) 
mice, which are deficient in CYP activity. High levels of CYP-mediated CVB of [14C]-FA and 
[14C]-DFC were observed in wild-type microsomes, but not in HRN™ microsomes. No UDPGA-
mediated CVB was detected in microsomes incubated with [14C]-FA. Wild-type and HRN™ 
mice were orally administered DFC or FA orally for 7days. At 100 mg/kg, FA caused a 
significant (p<0.05) time-dependent increase in plasma alanine amino transferase (ALT) in 
wild-type but not HRN™ mice. Aberrant liver histopathology and liver clinical chemistry were 
evident in HRNTM mice and treatment with DFC and FA “normalised” the elevated ALT levels.  
These data demonstrate that FA undergoes CYP mediated bioactivation and that HRNTM mice 
are well suited to investigations of metabolism, but not of liver toxicity, due to impaired liver 
function.    
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CHAPTER ONE 
 
1.0   INTRODUCTION 
 
1.1     CARBOXYLIC-ACID AND DRUG TOXICITY 
The carboxylic acid moiety occurs in many drug classes including anti-convulsants, 
hypolipidaemics, non-steroidal anti-inflammatory drugs (NSAIDs), quinolone antibiotics (e.g. 
levofloxacin), angiotensin receptor inhibitors (e.g. telmisartan), leukotriene receptor 
antagonists (e.g. montelukast) and some diuretics (e.g. furosemide) (Skoberg et al., 2008; 
Sawamura et al., 2010). Some drugs like celecoxib are also known to be oxidatively 
metabolised to carboxylic acid. In addition, many endogenous compounds like bile acids, keto-
acid, amino acids, and triglycerides also contain the carboxylic acid moiety. Because these 
endogenous compounds have a clearly-defined metabolic pathway, xenobiotics with similar 
structural features can be metabolised in a highly predictable manner.   
Many of the drugs containing a carboxylic acid functional group have been associated with 
idiosyncratic and other predictable forms of toxicity in experimental animals or in humans. It 
was reported that over 14% of drugs withdrawn from the market in the closing years of the last 
century were those containing carboxylic acid (Fung et al., 2001), and non-steroidal anti-
inflammatory drugs (NSAID) topped the list.  Literature search shows that severe forms of 
toxicity and adverse drug reaction of some NSAIDs are partly responsible for either failure to 
progress from development to the market or withdrawal from clinical use. 
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A review by Goldkind and Laine (2006) showed that bromfenac, ibufenac, and benoxaprofen 
were withdrawn principally due to hepatic injuries.  
What is responsible for this trend among this group of NSAIDs? It is possible that this could be 
due the one thing they have in common i.e. the carboxylic acid moiety.  
The carboxylic acid portion of these molecules is a substrate of UDP-glucuronosyltransferases 
(UGTs), which catalyse the conjugation of the drug to endogenous glucuronic acid to produce 
acyl glucuronides and/ or acyl iso-glucuronides. Carboxylic acids may also be metabolised by 
acyl-CoA-synthetase, resulting in the formation of acyl-CoA thioesters. These two products are 
electrophilic and highly reactive (Skoberg et al., 2008). In addition, there is the possibility to 
form acyl glutathione thioesters which may also be chemically reactive. 
 
 
Fig 1.1: Examples of carboxylic-acid-containing drugs 
3 
 
1.1.1     Acyl glucuronides 
Acyl glucuronides are formed by glucuronidation reaction catalysed by UGTs, the most 
relevant isoform in humans being the UGT2B7 expressed mainly in the liver, where a bulk of 
biotransformation takes place. Consequently, high levels of glucuronides are found in 
hepatocytes. This is further aided by hepatic uptake, which is mediated by transport proteins 
(e.g. the organic anionic transporting peptides, OATP) present on the sinusoidal plasma 
membranes of the liver. Acyl glucuronides of many compounds are excreted into the bile via 
active hepatobiliary transport, which in many instances is mediated by multi-drug resistance 
protein type 2 (MRP2).  Biliary concentration of acyl glucuronides has been observed to be 
about 5000 fold higher than in the circulating plasma (Seitz et al., 1998; Boelsterli, 2002). A 
commonly proposed mechanism of toxicity induced by acyl glucuronides is as a consequence 
of covalent binding with cellular proteins. Some of the initial findings on covalent binding of 
acyl glucuronides to proteins were undertaken by Smith et al., (1986) who observed that 
zomepirac acyl glucuronide irreversibly bound to human plasma protein in vivo and in vitro. It 
is understood that adduct formation with protein occurs by either a direct attack of the 
nucleophilic group of the protein with a resultant displacement of the glucuronic acid from the 
parent drug, or a base-catalysed reaction in which there is a series of positional isomerism 
culminating in ring opening on the glucuronide acid portion of the conjugate and exposing its 
keto group to nucleophilic attack by the amino group of the protein (Figure 1.2). The second 
mechanism is thought to be the main route of acyl glucuronide-protein adducts formation 
(Skoberg et al., 2008).  
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                   Source:  Skoberg et al., 2008 
 
 
Mechanisms by which acyl glucuronides might cause toxicity have been proposed. The first is 
via direct activation of neutrophils and macrophages, resulting in the release of 
proinflammatory mediators and cytokines. In an in vitro study, Wieland et al. (2000) produced 
acyl glucuronides of mycophenolic acid by incubating the parent drug with human liver 
microsomes. When the resulting acyl glucuronides were incubated with human mononuclear 
leukocytes, a time- and dose-dependent release of cytokines was observed, as were increased 
transcription and release of interleukin-6 and tumour-necrosis factor. If these events were to 
Fig 1.2: Proposed mechanisms of protein adduct formation by acyl glucuronides and acyl-coA 
thioesters  
5 
 
occur in vivo, they could result in an acyl-glucuronide-mediated immune response with its 
attendant toxicological implication. In addition to this, evidence that acyl glucuronides 
covalently bind with DNA to form adducts has been presented. Sallustio et al. (1997) 
demonstrated that the acyl glucuronide of clofibrate and gemfibrozyl could cause adducts with 
DNA resulting in strand breakage, which is a classical mechanism of genotoxicity. A third 
potential mode of acyl-glucuronide-induced toxicity is, as mentioned earlier in this section, 
covalent modification of cellular proteins with an attendant alteration of signal transduction, 
triggering of immune response against modified peptides and a likely loss of function of the 
affected protein (Boelsterli, 2002). There have been sketchy but relevant evidence that acyl 
glucuronide can result in loss of protein function. Such was the case with the acyl glucuronide 
of zomepirac which, when incubated with tubulin in vitro, caused covalent modification and 
impaired assembly of tubulin in a dose-dependent manner (Bailey et al., 1998). Tubulin is the 
main component of microtubules and is involved in key cellular processes which include 
segregation of genetic material, intracellular transport, and maintenance of cell shape and 
positioning of cell organelles (Unger et al., 1990). Therefore, were impairment of microtubule 
assembly to occur in vivo, this could be expected to result in an elimination of microtubule with 
cell death as a consequence (Unger et al., 1990). Another direct evidence of effect of acyl 
glucuronide of carboxylic acid-containing drugs on protein function was seen with suprofen, 
which is an NSAID withdrawn due to its renal effect, and was also seen to cause liver injury.  
Upon covalent binding, the acyl glucuronide of this NSAID was reported to produce 
remarkable loss in superoxide dismutase (SOD) activity (Chiou et al., 1999). Since SOD is an 
endogenous antioxidant, its depletion may result in oxidative stress and potentially cell death.   
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1.1.2           Acyl-CoA Thioesters 
Acyl-CoA thioesters are important for a number of cellular reactions which include biosynthesis 
of complex lipids, conjugation of endogenous and exogenous carboxylic acids to amino acids 
and the enzyme-catalysed S-acylation of proteins, which is a vital step in the regulation of 
activities of proteins involved in signal transduction (Hall and Quan, 1994). Endogenously, their 
formation is a sine qua non for fatty acid metabolism, elongation and formation of lipids. This 
reaction is catalysed by fatty acid CoA ligases. Unlike many acyl glucuronide metabolites, acyl 
CoA thioesters of drugs are highly unstable molecules which are not excreted from cells in vivo 
or in vitro in significant quantities. Their main fate is conjugation with amino acids such as 
glycine, taurine and carnitine esters, which predominantly takes place in the mitochondrial 
matrix.  The most common carboxylic acid conjugates are those with glycine and taurine (Sarda 
et al., 2012). Drugs that have been associated with metabolism to this class of conjugates 
include tolmetin, zomepirac, pivalic acid and valproate (Brass, 2002, Olsen et al., 2003; Olsen 
et al, 2005; Li et al, 2003). Experimentally, an indicator of the formation of acyl-CoA 
intermediates is detection of acyl-CoA-dependent metabolites in hepatocyte incubations, in 
bile or urine extracts (Skoberg et al., 2008). The chemical reactivity of acyl-CoA thioesters of 
carboxylic acid-containing drugs is due to the electrophilic carbonyl carbon, which enables 
them to readily attack the nucleophilic centres (thiol-, amino-, or hydroxyl- groups) in proteins 
and other components of the cell. It has been proposed that acyl-CoA thioesters could exert 
toxic effects by competition with CoA-activated intermediate fatty acids, which are formed 
during fatty acid synthesis. In addition, acyl-CoA thioesters have been found to bind covalently 
to proteins and can also react with glutathione via s-transacylation to form unstable 
glutathione conjugates, which could perhaps mediate toxicity (as has been proposed for acyl 
glucuronides). 
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This research project has focus on and examined two carboxylic-acid-containing drugs, one 
with a well-reported toxicity profile and the other with scant information in the literature due 
to its withdrawal from development as a potential anti-rheumatic therapy following liver injury 
observed in patients. The two drugs are diclofenac and fenclozic acid, respectively. 
 
1.2   DICLOFENAC 
Diclofenac 2-(2, 6-dichloranilino) phenylacetic acid is a non-selective Cyclo-oxygenase (COX) 
inhibitor developed in 1976 by CIBA Geigy, now Novartis, in an attempt to synthesise an 
NSAID with high efficacy and tolerability (Sallmann, 1986). A potent anti-inflammatory agent, 
diclofenac blocks the oxidation step in the conversion of arachidonic acid to prostaglandins, 
notably prostaglandin E2, which is a well-known mediator of inflammatory processes (Gan, 
2010) Inhibition of this pathway results in the alleviation of the cardinal manifestations of 
inflammation, namely redness, pain, swelling and fever. This has been exploited in 
management of such conditions as musculoskeletal complaints, especially arthritis, 
rheumatoid- and osteoarthritis, polymyositis, gout, and dental pain.  
NH
Cl OH
O
Cl
 
 
 
 
Fig 1.3: Diclofenac 
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1.2.1    Metabolism of Diclofenac 
 
In humans, diclofenac is mainly oxidatively metabolised by CYP2C9, giving rise to 4’-
hydroxydiclofenac (Tang et al., 1999). The 4’-hydroxy metabolite of diclofenac can also be 
produced by CYP2C8 (Sanjeev et al. 2002).  
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Furthermore, another important route for diclofenac metabolism in humans is 5-hydroxylation 
predominantly catalysed by CYP3A4.  Studies with human liver microsomes reveal that 
diclofenac is glucuronidated by the hepatic UGT2B7 isoenzyme (King et al., 2001).   
Fig 1.4: Metabolic fate of diclofenac in humans. As the main hepatic phase I enzyme for diclofenac metabolism 
in humans CYP2C9 biotransforms diclofenac to its 4’-OH metabolite. UGT2B7 is known to conjugatively 
metabolise diclofenac to an acyl glucuronide that can thereafter be metabolised to its 4’-OH metabolite. All 
these metabolites are known to form reactive species  
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This is considered to be the predominant metabolic route of this drug in humans since it has 
been estimated that 75% of its hepatic clearance is by acyl glucuronidation (Sanjeev et al. 
2002). In addition, both glucuronidation and 4’-hydroxylation may occur, resulting in formation 
of 4’-hydroxy acyl glucuronide. In vivo, metabolism and disposition of diclofenac is complex 
due to hepatobiliary metabolite excretion mediated by MRP2, hydrolysis of acyl glucuronides 
by the enteric β-glucuronidase enzyme and enterohepatic circulation. It has been proposed 
that these processes have toxicological implications (Tang, 2003), which are discussed in 
details below. In other species, a variety of conjugative metabolites of diclofenac have been 
elucidated.  The dog was observed to principally metabolise diclofenac by taurine conjugation, 
while in rat acyl glucuronidation followed by biliary excretion is a major metabolic route. In the 
rainbow trout, multiply-substituted glucuronides of diclofenac have been identified which 
include ether glucuronides and hydroxyl-substituted acyl glucuronides, as have 
hydroxysulphates (Kallio et al., 2010, Stierlin et al., 1979). Sarda and co-workers (2012) 
discovered some further novel metabolites in the mouse. From mouse urine, they observed that 
a taurine conjugate was the major metabolite and also identified a 4’-hydroxylated taurine 
conjugate. In addition they saw 4’- and 5-hydroxy ether glucuronide as well as a hitherto 
unrevealed conjugate which might be with glucose. There were also indolinone conjugates, 
which might have been formed due to a dehydration of the carboxylic acid moiety with a 
consequent ring closing forming a lactam ring. These coexisted with an ether glucuronide of a 
hydroxyl metabolite.  
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1.2.2   Role of Diclofenac Metabolism in Hepatotoxicity 
Diclofenac remains in clinical use despite its well-reported incidences of rare forms of 
idiosyncratic liver toxicity (Tang, 2003).  As early as 1981, there were reported cases of 
hepatitis in patients managed with diclofenac. In one case reported by Dunk et al., (1982), liver 
biopsy specimens showed a moderately severe acute hepatitis with canalicular cholestasis and 
Kupffer-cell proliferation, and plasma cells and eosinophils in the inflammatory infiltrate. 
These were reversed when the diclofenac treatment was withdrawn. A review by Boelsterli et 
al. (1995) linked NSAID-mediated hepatotoxicity (including diclofenac) with immunological 
reactions. A variety of investigative studies have indicated an association between diclofenac-
induced liver toxicity and biotransformation of the drug. The phenylamine portion of the 
structure is the principal target of oxidative metabolism, which is catalysed by CYPs and mainly 
involves hydroxylation to excreted metabolites (see above).  
 
 
 
 
 
 
 
 
Source: Boelsterli, 2003 
 
Fig. 1.5:  Formation of potentially reactive metabolites of diclofenac. P-benzoquinone imine 
formed from 5-OH-diclofenac is followed by S-glutathionylation and is excreted as urinary 
mercapturic acid in humans. CYP3A4 can also form a potentially reactive epoxide which at a 
high concentration can bind to and inactivate the enzyme in vitro. 
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However, diclofenac oxidation may also produce highly reactive epoxide (arene oxide) 
intermediates and quinone imines at the 5- or 4’- positions of the benzene rings of the 
molecule. In-vitro studies have demonstrated that epoxide formation from diclofenac is 
catalyzed by CYP3A4 and results in enzyme inactivation arising from protein adduct formation.  
Quinone imines are highly reactive electrophiles which react chemically with thiol groups on 
proteins as well as other endogenous thiol-containing cellular components. They also readily 
bind with glutathione (GSH) and at a high cellular concentration may result in GSH depletion 
and hence oxidative stress. In a study involving the use of rat hepatocytes, induction of the 
cytochrome P450 system was shown to result in an increased potency of cytotoxicity of 
diclofenac (Schmitz et al. 1992). This cellular event was associated with an uncoupling of the 
mitochondrial oxidative phosphorylation, oxidative stress, and induction of immune responses. 
As earlier mentioned, the carboxylic acid moiety of diclofenac is a substrate for UGTs and 
product is the chemically reactive acyl glucuronides (diclofenac 1-o-β acyl glucuronide) and/or 
iso-glucuronides. The latter are formed via a series of isomerisation steps that culminate in ring 
opening and exposure of the keto group of the glucuronic acid, which is highly electrophilic 
and is resistant to the β-glucuronidase enzyme.  Acyl glucuronides (AG) of diclofenac are 
substrates for the active transporter MRP2, which concentrates these metabolites in the bile 
from where they are emptied into the gastro-intestinal tract, thereby setting stage for entero-
hepatic circulation. Within the gastro-intestinal tract, enteric microflora release β-
glucuronidase which cleaves glucuronide conjugates thereby releasing the unconjugated drug 
for further absorption and metabolism by the liver (Boelsterli, 2003). Hydrolysis of acyl 
glucuronides can also be achieved by non-specific esterases or a simple aqueous hydrolysis of 
the metabolite which occurs at alkaline pH, enabling recirculation of diclofenac from bile into 
the general circulation. These products are transported by the MRP2 into the biliary tree as 
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illustrated below (Figure 1.6). Adducts can be formed between the AGs and proteins in the bile 
canaliculus, while the enteric β-glucuronidase can effect a cleavage of the AG thereby 
releasing the parent compound, starting enterohepatic cycling. On the other hand, iso-
glucuronides, which are not glucuronidase-labile, do not enter the cycle. This process is known 
to increase the exposure time of the liver to diclofenac and its metabolites, hence providing 
higher chances for cellular insults arising from formation of reactive intermediates.  
 
 
Source: Boelsterli, 2003 
 
 
Boelsterli (2003) has pointed out that diclofenac-induced liver injury in humans typically is 
characterised by elevated plasma amino transferase activities alongside jaundice and in some 
Fig. 1.6: Disposition of diclofenac acyl glucuronide (AG), hydroxydiclofenac acyl glucuronide, and iso-
glucuronides in the liver.  
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instances cholestatic hepatocellular injury, that hypersensitivity reactions may also arise and 
that there is a delayed onset of manifestation. These features indicate that liver injury is a 
gradual and cumulative process in susceptible patients which ultimately can result in massive 
insult affecting the hepatobiliary excretory system. Reactive metabolites of diclofenac have 
high affinity for sulphydryl groups and amino groups on protein and non-protein peptides, 
enabling them to interact chemically with cellular and plasma proteins and resulting in adduct 
formation. One of the consequences of this adduct formation is the down-regulation of the 
activity of CYPs. Shen et al. (1997) reported that adducts formed in vivo caused a 72% decrease 
in cyp2c11 activity, which is a male-specific enzyme, in rats.  Yasumori and co-workers (1987) 
had earlier shown that rat cyp2c11 has 76% identity and 85% homology to human CYP2C9, 
which metabolises the drug in humans. However, Masubuchi et al (2001) reported that 
metabolites of diclofenac did not inhibit CYP2C9 activity in human liver microsomes, although 
evidence of metabolite-mediated inactivation of human CYP3A4 was obtained, with epoxides 
suspected to be responsible. One consequence of covalent modification of proteins is 
haptenation, which has the potential to trigger drug-specific adaptive immunological 
reactions.  Protein adduct formation might also result in inactivation of crucial protein 
functions such as cell signalling, resulting in a disregulation of cellular functions and tissue 
injury (Boelsterli, 2002). In addition to raising the possibility that covalent modification of 
CYP3A4 could play a role in the mechanism of diclofenac-induced liver injury, these results also 
indicate a potential for drug-drug interactions, in view of the fact that over 50% of drugs used 
clinically are metabolised by this enzyme. As mentioned in the previous section, there is 
evidence that reactive acyl glucuronide of diclofenac can form adducts with liver proteins.  
Kretz-Rommel and Boelsterli (1994) demonstrated the potential of diclofenac acyl 
glucuronides for covalent adduct with rat liver microsomal protein via the imine mechanism 
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described above which has been linked with immune-mediated toxic response. It has also been 
shown that diclofenac exposure of mice causes haemolytic anaemia. This might be linked to 
the reported cases in which metabolites of diclofenac covalently bind with erythrocyte 
membrane proteins, thus linking covalent modification of membrane protein with haemolysis 
(Ware et al., 2001). Genetic polymorphism has been reported in the expression of the CYP2C9 
gene with the main ones being CYP2C9*1, CYP2C9*2, CYP2C9*3. However, none of these 
polymorphic forms predisposes to diclofenac-induced liver injury (Aithal et al., 2000, Pachkoria 
et al., 2007) 
 
1.3       FENCLOZIC ACID 
Fenclozic acid (FA) was developed in the late 1960’s by Imperial Chemicals Industry (ICI), which 
is a predecessor company of AstraZeneca, as a potent anti-inflammatory, antipyretic and 
analgesic agent (Hepworth et al., 1969).  
Cl
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Fig 1.7:  Fenclozic acid 
Patented as 'Myalex®', and internally coded as ‘ICI 54, 450’, fenclozic acid was remarkably 
potent at oral doses of 2.5-100mg/kg as anti-inflammatory agent in studies undertaken in 
animals.  These involved evaluation of carrageenin-induced oedema in rats, adjuvant-induced 
inflammation in mice and ultraviolet-light-induced erythema in guinea pigs. The toxicity of the 
drug was evaluated in numerous species and a good overall safety profile was observed. In rats, 
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LD50 were 850 mg/kg (oral) and 300 mg/kg (iv), while in mice it was 1000mg/ kg (oral) and 250 
mg/kg (iv). A three-month chronic toxicity study at a maximum dose of 80 mg/kg in rats caused 
death due to duodenal ulceration and peritonitis. With a half life of over 24 hours, FA had a 
high serum concentration and binding (Hepworth et al., 1969; Newbould, 1969). 
 
1.3.1   Pharmacology and Toxicology of Fenclozic acid in human volunteers 
Pharmacokinetic studies were carried out in healthy human volunteers and arthritic patients 
treated with FA at doses of 25-200 mg/kg twelve hourly for up to one week (Chalmers et al., 
1969a).  There was a longer serum half life in arthritic patients than in healthy volunteers, a 
high volume of distribution in all volunteers and a generally similar pharmacokinetic profile 
when compared with preclinical animal species. This was followed by an efficacy study which 
used a double-blind cross-over trial in in-patients with rheumatoid arthritis. When compared 
with acetyl salicylic acid, FA exhibited anti-rheumatic effects at 200-, 300- or 400 mg daily 
dose as compared with 3.6g of aspirin, accompanied with fewer side effects than aspirin. 
However, half life was seen to be greater than 40 hours (Chalmers et al., 1969b). However, 
further investigations carried out at different facilities in the UK revealed that FA induced an 
unacceptable increase in liver transaminase enzyme levels with a simultaneous development of 
jaundice after a minimum of fourteen days of treatment (Hart et al., 1970). This resulted in the 
withdrawal of FA from clinical trial and suspension of its registration as a potential 
antirheumatic drug.  
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1.3.2    Metabolism of Fenclozic Acid 
 Bradbury et al. (1981) reported the presence of hydroxylated metabolites and taurine 
conjugate of [14C]-FA after administration of oral doses of 2- and100 mg/kg in urine of free 
range rats.  
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Similar doses administered intraduodenally to anaesthesised male rats yielded taurine and 
glucuronide conjugates as well as hydroxylated and decarboxylated FA which were excreted in 
the urine and the decarboxylated metabolite which was detected in urine and bile. Foulkes 
(1970) had previously reported that a dilute aqueous or chloroform solution of FA underwent 
photochemical transformation resulting in decarboxylation, which was reduced to 3.5% when 
Fig. 1.8: Metabolism of Fenclozic acid: Some in vivo metabolites of fenclozic acid as described by Foulkes et 
al. (1970). Question marks on the CYP and UGT show that the specific enzymes involved are as yet 
uncharacterised.   
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the solution was prepared in pH 7.0 phosphate buffer and stored in the dark. In view of this, it 
was then postulated that the observed decarboxylated metabolite detected in rat, dog and 
monkey urine might be a result of an initial chemical reaction that took place on the dose 
solution prior to administration. Foulkes (1970) also reported detection of a 4-phenyl hydroxyl 
metabolite of FA in the rat and dog urine. Monkey, rat and dog urine also yielded a 
glucuronide of FA, while rat bile was found to contain the hydroxyl- metabolite and a 
glucuronide conjugate. Faecal materials were only seen to contain the parent compound and 
unconjugated metabolites. This study singled out the monkey as a species that extensively 
metabolised FA to its glucuronide conjugate, with little or no evidence of oxidative 
metabolism. In addition, analyses undertaken recently within AstraZeneca in C57BL6J and 
HRN™ mice revealed in vivo metabolism of FA to carnitine and glycine conjugates (Pickup et 
al., unpublished).  
 
1.4 THE HEPATIC CYTOCHROME P450 REDUCTASE NULL (HRN™) MOUSE MODEL 
Gene knockout mice are very powerful tools for exploration of the role played by specific 
enzymes in metabolism and toxicity of chemicals in vivo (Gonzalez, 2001). A good illustration 
of the value of this approach has been provided by Zaher et al. (1998), who observed a longer 
survival time in CYP 1a2/2e1 double knockout mice as against wild-type mice exposed to 
paracetamol which could be attributed to an absence of metabolic bioactivation in the 
knockout animals. However, results obtained with knockout mice can be affected by 
compensatory upregulation of expression of other CYP enzymes. An alternative approach 
would be to produce mice in which all CYP activity has been impaired.  This has been achieved 
for liver CYPs via the generation of the hepatic Cytochrome P450 reductase null (HRN™) 
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mouse, which is a genetically-modified strain that lacks the electron donor, NADH-cytochrome 
P450 oxidoreductase (POR) gene. POR is a 78kDa membrane-bound flavoprotein which 
catalyses the transfer of electrons from NADPH to CYPs located on the endoplasmic reticulum 
and to other microsomal enzymes and electron acceptors (Wang, 2005). Its deletion results in 
the simultaneous inactivation of all the hepatic CYPs resident in the endoplasmic reticulum 
(Henderson et al., 2003), while the mouse remains essentially healthy, viable and fertile (Wang 
et al., 2005). The HRN™ mouse model was created in 2003 by insertion of LoxP sites into 
introns 4 and 15 of the POR gene (Figure 1.9). When these mice were crossed with those that 
express the Cre recombinase off the albumin promoter, the offspring exhibited lack of the 
liver-specific POR in hepatocytes.    
 
Modified from: Henderson et al., 2003  
 
Due to their lack of activity of functional hepatic CYPs, the HRNTM mice have a compromised 
ability to metabolise drugs and to produce bile acids, which is a CYP-dependent process 
causing a reduction in concentrations of circulating cholesterol and triglycerides. Livers from 
HRN™were found to be larger and paler than those of the corresponding wild-type strain and 
they exhibited elevated serum alanine amino transferase (ALT) activities, which is indicative of 
Fig. 1.9: Modification of the POR gene to effect a deletion of the CYP reductase (CPR) enzyme. Squares 
represent the CPR genes while the triangles stand for the LoxP sites which cleave off the CPR genes located 
between exons 5 and 15. 
 
19 
 
some liver damage and/or altered hepatocyte turnover rate.  In addition, there was a profound 
increase in the expression of xenobiotic-related CYP proteins, although these enzymes were 
catalytically inactive due to a lack of the POR gene. 
Studies have shown the utility of HRNTM mice in pharmacological and toxicological research. 
These include efficacy and metabolism studies, metabolite profiling (Sarda et al., 2012), 
toxicokinetic studies and mechanistic studies (Henderson et al., 2003). It is important to note 
that although deletion of the hepatic POR impairs CYP activity in livers of HRNTM mice, it does 
not affect extraheptic CYPs.  Therefore the model can also be used to assess the contribution of 
extra-hepatic CYP activity, such as in the lungs, kidneys and gastro-intestinal tract, to in vivo 
drug metabolism.  
 
1.5  AIMS AND OBJECTIVES OF STUDY 
The primary goal of the study was to gain novel insight into the role played by hepatic 
metabolism in the metabolic bioctivation and liver toxicities of diclofenac and fenclozic acid.  
The work was undertaken in vitro and in vivo, using mouse models.  In vitro metabolic profiling 
and covalent binding studies were undertaken using liver microsomes from normal mice and 
from HRNTM mice which were incubated with both drugs in the presence of cofactors which 
supported CYP- or UGT- dependent metabolism.  Hence the mechanism of bioactivation of 
fenclozic acid into reactive metabolites was explored by means of in vitro tools. In addition, 
normal mice and HRNTM mice were dosed in vivo with both compounds, following which 
evidence of liver injury was sought by analysis of serum clinical chemistry and liver 
histopathology and metabolism of the compounds was explored by metabolite profiling.   
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CHAPTER TWO 
 
2.0  MATERIALS AND METHODS 
2.1  Materials 
2.1.1  Chemicals and Reagents 
 
[14C]-fenclozic acid was obtained from Isotope Chemistry (AstraZeneca R&D, Macclesfield, 
UK) it had a purity of >99% and a specific activity of 60.5 mCi/mmol. [14C]-diclofenac was 
obtained in two batches.  The first batch was obtained from American Radiolabelled Chemicals 
Inc (St Louis Missouri, USA), it had a purity of 99% and a specific activity of 55mCi/mmol The 
Second batch was obtained from Isotope Chemistry (AstraZeneca R&D, Mölndal (Mölndal, 
Sweden)., it had a purity of 98% and a  specific activity of 57.24 nCi/nmol. Fenclozic acid was 
obtained from Compound Management (AstraZeneca, R&D, Macclesfield, UK). Diclofenac was 
obtained from Sigma-Aldrich Company Ltd (Poole, Dorset, UK). Ultima Gold liquid scintillation 
cocktail was obtained from Perkin Elmer (Waltham, USA). PierceTM BCA Protein Assay Kit was 
obtained from Thermo Scientific (Rockford Illinois, USA). Formic acid was obtained from VWR 
International Ltd (Poole, Dorset, UK). 10% Sodium dodecyl sulphate solution (Applichem 
GmbH, Darm Stadt, Germany) EnzyChrom™ Alanine Transaminase Assay Kit was obtained from 
BioAssay Systems (Hayward, USA).  All other reagents were obtained from Sigma-Aldrich 
Company Ltd (Poole, Dorset, UK). Safety assessment/hazard categorisation was done on each 
of them and the protocol that involve their use. 
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2.1.2  Biological Samples 
Snap frozen mouse livers from male C57BL6J mice (10-11 week old) or male HRN™ (Hepatic 
Cytochrome P450 reductase null; 12-27 weeks old) mice were obtained from Biospecimens 
Unit, AstraZeneca R&D (Macclesfield, UK). Snap frozen beagle dog livers (weeks old) were 
obtained from Biospecimens Unit, AstraZeneca R&D (Macclesfield, UK).Mouse plasma from 
male C57BL6J mice (10-11 week old ) was obtained from Biospecimens Unit, AstraZeneca 
R&D, (Macclesfield, UK).  
2.1.3  Animals 
Thirty male C57BL6J mice (7-8 weeks old) were obtained from Charles River (Margate, UK). 
Fourteen male HRN™ mice (4-11 weeks old) were obtained from Taconic Farms Inc (German 
Town, New York, USA). All animals were kept in the Rodent Unit of AstraZeneca R&D facility, 
Macclesfield, UK. They were individually housed in standard conditions, freely fed with 
pelleted diets (R&M No.1, E.SQC pelleted diets, supplied by Special Diets Limited, England) 
and water from the site drinking water. Animals were exposed to a 12-hour light and 12-hour 
dark cycle. All procedures involving the use of animals were carried out in accordance with the 
approved licenses and guidelines of the British Home Office (Animals and Scientific 
Procedures) Act of 1986. They were allowed to acclimatize for at least one week before 
commencement of study. 
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2.2  EXPERIMENTAL PROTOCOLS 
2.2.1  IN VITRO ASSAYS 
2.2.1.1  Preparation of subcellular fractions 
The procedure was based on the method reported by Graham (2002). Briefly, frozen livers were 
thawed at room temperature, weighed, placed in 1.15% KCl solution and scissors minced to 
remove the blood. The KCl solution was drained off and then 9 volumes of ice cold SET buffer 
pH 7.4 (0.25 M sucrose, 20 mM Tris base, 5 mM EDTA) was added. The samples were then 
homogenised using a Potter homogeniser (B. Braun Biotech Int’l GmbH, Melbungen Germany) 
6 strokes to produce a 10% homogenate. The homogenates were centrifuged at 1,800 g for 10 
mins at 4°C using a Sorvall® RT7 bench top centrifuge (Kendro Lab Products , USA). The pellet 
was discarded and the supernatant (S1) centrifuged at 3,000 g using a Sorvall® Discovery 90-
SE ultra centrifuge (Kendro Lab Products , USA) for 10 mins at 4°C. Both the heavy 
mitochondrial pellet (HM) and supernatant (S2) were kept. The HM pellet was washed by re-
suspending in mitochondrial buffer (0.2 M mannitol, 50 mM sucrose, 1 mM EDTA, 10 mM 
HEPES),and then centrifuging at 3000g using a  Sorvall® Discovery 90-SE ultra centrifuge for 
10 min at 4°C. The supernatant (S3) was discarded and the HM pellet reconstituted in 
mitochondrial buffer at 1 ml/g liver. Aliquots (250 µl) were stored frozen at -80°C. The 
supernatant (S2) was centrifuged at 17,000 g using a  Sorvall® Discovery 90-SE ultra centrifuge 
for 15 min at 4°C. The supernatant (S4) was stored on ice whilst the light mitochondrial pellet 
(LM) was washed by re-suspending in mitochondrial buffer and then centrifuging at 17,000 g 
using a  Sorvall® Discovery 90-SE ultra centrifuge for 15 min at 4°C. The supernatant was 
discarded and the LM pellet reconstituted at 1ml/g liver. Aliquots (250 µl) were stored frozen 
at -80°C.  
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Supernatant (S4) was centrifuged at 105,000g using a Sorvall® Discovery 90-SE ultra 
centrifuge for 70 mins at 4°C. The supernatant (S5; cytosol) was stored in 1 ml aliquots at -80°C 
for possible subsequent analysis. The pellet (microsomal pellet) was washed by re-suspending 
in KCl/Tris buffer (20 mM Tris base, 1.15% KCl) was and then centrifuged at 105,000 g for 70 
mins at 4°C. The supernatant was discarded and the microsomal pellet suspended in SET buffer 
at 1mL/g liver.  Aliquots (250 µl) were stored frozen at - 80°C. 
 
2.2.1.2  Protein Assay 
Microsomes and mitochondrial pellets were analysed for protein using the BCA protein assay 
(Smith, et al. 1985) which is a colourimetric method based on the protein-induced biuret 
reaction that causes a reduction of Cu (II) to Cu (I) and a subsequent chelation of Cu (I) by two 
molecules of bicinchoninic acid (BCA) to form a water-soluble purple-coloured complex that 
absorbs strongly at 562nm, the intensity of which increases with increasing protein 
concentration.    
A 10 point standard curve (0 - 2 mg protein/ml) was produced by serially diluting the 2mg/ml 
bovine serum albumin protein standard using distilled water. The microsomal and 
mitochondrial samples were diluted (1:50, 1:100 and 1:200) to ensure the protein values fell 
within the range of the standard curve. Aliquots (25 µl) of both the protein standards and the 
sample dilutions were pipetted into a clear-bottom 96-well plate and then 200 µl Working 
Reagent (WR 50 parts of reagent A (sodium carbonate, Sodium bicarbonate and Sodium 
tartrate in 0.1 N sodium hydroxide) to 1 part reagent B (4% cupric sulphate)) was added. The 
plate was then incubated at 37°C for 30 minutes, cooled for 2-3 mins and absorbance 
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determined using an Envision plate reader (PerkinElmer CA, USA) and a wavelength of 562nm. 
A standard curve was constructed and protein concentration calculated and expressed as mg 
protein/ml. 
 
2.2.1.3  Succinate Dehydrogenase (SDH) Assay  
Mitochondrial SDH was determined according to the method described by Green et al. (1955). 
It is an assay that measures change in absorbance (at 500nm wavelength) due to reduction of 
cytochrome c in the biological sample in the presence of cyanide. Briefly, to each of two 1 ml 
cuvettes 100 µl of 0.1M phosphate buffer, 100 µl of 10 mg/ml bovine serum albumin, 50 µl 
potassium cyanide, 595 µl of distilled water, 5 µl of the mitochondrial pellets and 100 µl of 
cytochrome c from equine heart were added. Contents of the cuvette were mixed by inversion 
and the absorbance ‘blanked’ in an Agilent 8453 UV-Visible Spectrophotometer (Agilent 
Technologies, California, USA) at a wavelength of 550nm. The reaction was started by adding 
sodium succinate (50 µl, 0.1 M). The cuvette was mixed by inversion and the change in 
absorbance determined kinetically for 3 minutes. Enzyme activity was calculated using the Beer 
Lambert law (extinction coefficient of 19.7mM-1.cm-1) and was expressed as nmol reduced 
cytochrome c/min/mg protein.  
 
2.2.1.4  Cytochrome c Reductase Assay 
The assay was carried out using a Cytochrome c Reductase (NADPH) assay kit (Sigma-Aldrich 
Company Ltd, Poole Dorset, UK) containing the Assay Buffer (300 mM potassium phosphate 
buffer, 0.1mM EDTA), Enzyme Dilution Buffer (300 mM potassium phosphate buffer, 0.1 mM 
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EDTA and 0.5 mg/mL bovine serum albumin), cytochrome c from equine heart, NADPH and 
0.42 units/mL cytochrome c reductase (NADPH). The working solution was 36 µM of 
cytochrome c in assay buffer. NADPH stock solution was 40 mg/mL in water. The positive 
control was prepared by diluting an aliquot of the cytochrome c reductase (NADPH) between 
10 and 100 fold with the enzyme dilution buffer just before assaying. Each set of reactions 
required a total of 75 µl of the diluted positive control. The enzyme preparations (samples and 
control) were kept on ice. The working solution and the NADPH stock Solution were warmed 
to 25˚C just before use. The spectrophotometer (Agilent 8453 UV-Visible Spectrophotometer, 
Agilent Technologies, United States, California, USA) was set to 550 nm and kinetic program 
was run at 25˚C. Working solution (950 µl) and 50 µl of microsomal sample or positive control 
were placed in a 1 ml cuvette and mixed by inversion. The spectrophotometer was blanked and 
the reaction was started by addition of 100 µl of NADPH solution. The absorbance of the 
reaction mixture was read by the kinetic programme at 550 nm. The cytochrome c reductase 
activity in the microsomal samples were calculated and expressed as pmol/min/mg protein. 
 
 
2.2.1.5  Covalent Binding Assay 
Covalent binding assay (CVB) was conducted using the method previously described by Day et 
al. (2005). Dog, C57BL6J or HRN mouse liver microsomes (1 mg/ml protein) were incubated in 
a 96-well nunc plate (plate 1)  containing 0.1M potassium phosphate buffer plus 10mM MgCl2, 
pH 7.0 pre-warmed to 37oC and either 2 mM NADPH (with or without 1 mM 
1-aminobenzotriazole (ABT)), 4mM UDPGA or no co factor in a final volume of 500 µl. The 
samples were pre-incubated for 9 mins on heater block (Techne, Dri-Block®, DB-2D) set to 
26 
 
38.5°C and then the reaction started by the addition of either 10 µM [14C]-fenclozic acid or 
[14C]-diclofenac. The plate was then transferred to an incubator and incubated at 37
 °
C for 1 
hour. Covalent binding at T=0 and t=60 mins was determined by taking a 200 µl aliquot from 
each well of plate 1 and adding it to a 2ml 96-well nunc plate (plate 2) already containing 
300µl (1.5 volume) of cold acetone to terminate the reaction and precipitate the protein. A 
further 500 µl (2.5 volume) of cold acetone was added to fully precipitate the protein and plate 
was mixed (Heldolph Instruments, Schwabach, Germany). The plate was then stored at 4oC to 
precipitate the protein. Metabolism at T=0 and t=60 mins was determined. A 50 µl aliquot 
(from plate 1) was transferred into another 1 ml 96-well plate (plate 3) already containing 50 µl 
of cold 3% formic acid in acetonitrile. The plate was then stored at -20oC prior to analysis by 
HPLC-RAD-MS.    
Non specific binding was determined by incubating microsomes or mitochondrial samples in 
the absence of test compound for 1 hour at 37ºC and then ‘back-adding’ 10µM of [14C]-
fenclozic acid or [14C]-diclofenac. The samples were then treated as for the T=60 covalent 
binding samples. The protein pellets in plate 2 was washed with 80% methanol and collected 
on to Whatman GF/B fired filter paper using the Brandel 96-sample cell harvester (Brandel Inc, 
Maryland, USA). The protein collected on individual filter discs were transferred into a 
scintillation vial and 1 ml of 5 % sodium dodecyl sulphate (SDS) solution added to solubilise the 
protein. The vials were covered and incubated overnight at 55°C. The next day, the vials were 
swirled gently and returned to the oven for another 1 hour. The protein content was then 
determined using the Pierce BCA Protein Assay Kit using BSA as a standard and the BioTek® 
Synergy HT Multidetection Microplate Reader with KC4 software.  Ultima Gold scintillation 
fluid (5 ml) was added to each vial swirl-mixed and bound radioactivity was measured by liquid 
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scintillation counting on a Packard 1900TR analyser. The level of non-extractable radioactivity 
covalent binding (CVB) was expressed as: pmole equivalents/ mg protein using the specific 
activity of the dose solution given and the protein levels of each sample. All incubations were 
performed in duplicates. 
 
2.1.6  Metabolite profiling by HPLC-RAD 
 
 The acetonitrile quenched samples from the CVB assay were transferred to a 500 µl Eppendorf 
tube, centrifuged (Eppendorf, Stevenage, UK) at 1000 rpm for 10 minutes and the supernatant 
collected and stored at -20°C for subsequent metabolite identification.  
“Samples were injected (50 µl injection volume) onto and separated on a Hypersil Gold C18, 5 
μm, 250 × 4.6 mm column (ThermoScientific, Warrington, UK) with a 3 µm (C18) pre-column 
filter (Hichrom Ltd., Reading, UK), all maintained at 30°C and eluted over 60 min using Agilent 
1200 Series pumps (Agilent Technologies, Stockport, UK) at a flow rate of 1 mL/min. The 
aqueous mobile phase (solvent A) was 10 mM ammonium acetate (unadjusted, ca.pH 6.8) with 
acetonitrile constituting the organic mobile phase (solvent B). The initial mobile phase 
consisted of 5% solvent B, which was increased to 14% over a period of 4 min, then further 
increased to 34% in 41 min, and to 45% over 5 min before finally increasing to 95% over 0.1 
min. This high organic concentration was maintained for 5 min before returning to 5% solvent 
B for column equilibration for 5 min prior to subsequent injections. The post-column eluent 
was split 1:5 v/v between the mass spectrometer and radiodetector, respectively, using a 
QuickSplit(tm) binary fixed flow-splitter (Analytical Scientific Instruments, El Sobrante, CA), to 
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enable simultaneous MS and radiodetection. Radiochemical detection was performed on-line 
using a LabLogic β-Ram 3 detector (LabLogic Systems Ltd., Sheffield, UK) with a 500 μL liquid 
flow cell and Ultima Flo-M scintillation cocktail (Packard Instruments, Pangbourne, UK) 
running at 1.6 mL/min (ca. 2:1 v/v scintillant/eluent). The data were collected and analysed 
using LAURA integration software version 3.4.1.10e (LabLogic Systems Ltd., Sheffield, UK).”
  
 
2.2.2  IN VIVO STUDIES 
2.2.2.1  Preparation of Dose Formulations 
Diclofenac was dissolved in the dose vehicle, 0.1 M sodium phosphate buffer pH 7.7, at room 
temperature at concentrations of 1, 2 and 3 mg/ml. Fenclozic acid was dissolved in 0.1 M 
sodium phosphate buffer pH 7.7 with warming to 37 ⁰C at concentrations of 5 and 10 mg/ml. 
On cooling to room temperature the 5 mg/ml fenclozic acid dose formulation stayed in 
solution, however the fenclozic acid in 10 mg/ml formulation came out of solution. As a result 
this formulation had to be prepared fresh daily for the duration of the studies. Stability studies 
on the 1, 2, 3 mg/ml diclofenac and 5 mg/ml fenclozic acid dose formulations performed by 
the Analytical Chemistry Laboratory, (Drug Metabolism and Pharmacokinetics Kinetics (DMPK) 
Unit, AstraZeneca R&D, Macclesfield, UK) showed that these formulations were stable when 
stored in amber bottles at room temperature for 10 days. Aliquots of each of the dose 
formulations were kept for analysis.  
 
 
29 
 
2.2.2.2  Dose-range-finding (DRF) study in C57BL6J mice 
Thirty male C57BL6J mice were randomised by body weight, 5 animals per group so that the 
mean weight for each group was within 5% of the control group and allowed to acclimatize for 
at least 1 week prior to the start of the study. The study was designed such that the control 
animals (group 1) and the low dose diclofenac (group 2, 10 mg/kg/day) and fenclozic acid 
(group 5, 50 mg/kg/day) animals were exposed to the compounds for a period of 7 days with 
close monitoring. Providing the animals tolerated these doses, subsequent animals were 
exposed to the middle and high doses of diclofenac (20 and 30 mg/kg/day, groups 3 and 4) 
and high dose fenclozic acid (100 mg/kg/day, group 6). 
The body weight (BW), food consumption (FC) and clinical observations (CO) for each animal 
were monitored daily commencing 3 days prior to the start of the study. The first day of study 
was designated day 1 while the day prior to dosing was designated day -1. A blood sample (50 
l) was taken from each animal into lithium-heparin tubes by tail bleeding on day –1 for the 
determination of pre-dose plasma ALT levels, The sample was centrifuged at 3000 g for 10 min 
at  4°C and the resultant plasma stored frozen at - 80 ⁰C. In accordance with the Home Office 
license approved for the study, dose formulations were administered daily for 7 days by oral 
gavage at a volume of 10 ml/kg body weight for all the dose levels—10, 20 and 30 mg/kg body 
weight for diclofenac; 50 and 100 mg/kg BW for fenclozic acid —based on the body weight 
determined immediately prior to dosing. Mice in the control group received dose vehicle 
alone, sodium phosphate buffer solution (pH 7.7). The animals were dosed between 08:00 and 
12:00 hours on each day and closely monitored for the first 3 hours after each dose. Any mouse 
that demonstrated signs of toxicity and distress that exceeded the mild severity limit of the 
Home Office license would have been terminated and necropsied pre-terminally. Additional 
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blood samples for the determination of plasma ALT concentration were taken by tail bleeding 
the animals prior to dosing on days 2 and 4 of the study. The animals were terminated on day 8, 
24 hours following the last dose. Immediately prior to termination urine samples were 
collected from each animal. The animals were transferred to a clean plastic cage for and any 
urine in the cage at the end of this time was collected, mixed with an equal volume of 
deionised water and snap frozen in liquid nitrogen. The samples were stored frozen for possible 
subsequent metabolite analysis by HPLC-MS    
 
2.2.2.3  HRN™ Study 
 
Fourteen male HRN™ mice were randomised as described above and divided into 3 groups. 
The control group contained 4 mice and received the dose vehicle alone. The remaining two 
groups contained 5 mice each and they received the maximum tolerated dose for the 2 
compounds determined in the DRF study—30 mg/kg/day diclofenac and 100 mg/kg/day 
fenclozic acid. The formulations were administered between 08:00 and 12:00 hours on each 
day for 7 days with close monitoring for the first 3 hours after each dose as for the DRF study..  
Blood and urine samples were collected as in the DRF study. 
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2.2.2.4  Necropsy 
Animals were euthanized under halothane anaesthesia. Depending on the volume that could 
be collected, about 1 ml blood was collected by cardiac puncture via the vena cava and 
transferred into lithium heparin tubes. An aliquot of the whole blood (20 µl) was diluted with 
an equal volume of cold water, two volumes cold 3% formic acid in acetonitrile was added and 
the sample centrifuged at 1,500 g for 10 mins. The supernatant was collected, mixed with an 
equal volume of cold deionised water, snap-frozen in liquid nitrogen and stored frozen at -
80ºC for possible subsequent metabolite analysis by HPLC-MS. The remaining plasma was 
transferred to clinical pathology laboratory for biochemical analysis. The liver was excised, 
examined for any abnormalities and weighed intact. The gallbladders from the mice were 
removed, snap-frozen in liquid nitrogen and stored frozen at -80ºC for possible subsequent 
metabolite analysis by HPLC-MS. The left lateral lobe of the liver and samples of the intestines, 
the jejunum, ileum, colon, caecum, rectum, oesophagus and stomach/duodenum, were all 
fixed and preserved in buffered formalin for subsequent pathological analysis. The cranial, 
thoracic and abdominal cavities were visually examined for the presence of any abnormalities.  
   
2.2.2.5  Clinical Chemistry 
Lithium heparin blood samples obtained on day 8 were centrifuged in a Sorvall® RT7 centrifuge 
at 3000 rpm at 4°C for 10 minutes.  The resultant plasma was collected, transferred into 
analyser cups and the samples processed for alanine aminotransferase, aspartate 
aminotransferase, glutamate dehydrogenase, bile acids, alkaline phosphatase, total bilirubin, 
total protein, calcium, triglycerides, cholesterol, blood glucose, creatinine and urea on the 
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Roche P Modular Automated Chemistry analyser. Aliquots (about 20µl) of the plasma were 
taken for the determination of ALT using the manual ALT assay to serve as a comparison 
between manual and automated methods on day 8 of the study. 
 
2.2.2.6   Manual Alanine Amino transferase (ALT) Assay  
 Plasma ALT concentration was determined colourimetrically using an EnzyChrom™ Alanine 
Transaminase Assay Kit (Bioassays Systems, Hayward, CA, USA). Working Reagent for the 
sample and standard wells was prepared as follows: (200 µl Assay Buffer, 5 µl Co substrate, 1 µl 
LDH and 4 μl NADH). The reagent was vortex mixed and warmed to 37°C in a water bath. To 
prepare the blank reagent for the Blank well, all the reagents for the working reagent above 
with the exception of NADH which was replaced with water.  
Plasma (10 μl of 1:2, 1:10 or 1:40 dilutions) was pipetted into separate wells in a 96-well plate, 
with 20 µl of deionised water pipetted into the NADH standard and blank wells. Then, 200 µl 
of Working Reagent was added to each sample and standard well and 200 μL of blank reagent 
to the blank well. The plate was mixed on a plate mixer (Heldolph Instruments, Schwabach, 
Germany) for about 10 seconds and transferred to the Envision plate reader (PerkinElmer CA, 
USA) and the rate of NADH consumption determined kinetically at 340 nm and 37°C for 40 
minutes. Since NADH consumption in the reaction is proportional to the ALT levels, enzyme 
level for each sample was calculated by subtracting the absorbance values at 5-minute time 
interval within which an initial linear plot was obtained. This was also calculated for the NADH 
Standard and the blank. The ALT levels were calculated using the formula below, assuming 
time intervals of 5 minutes: 
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2.2.2.7  Histopathology of the Liver 
Livers were trimmed and placed into cassettes, processed with a Thermo Excelsior automated 
tissue processor (Thermo Scientific, Cheshire, UK), and embedded into paraffin wax using Leica 
EG 1160 Tissue Embedder (Leica Microsystems, Wussloch, Germany).  Sections were cut at 4 
microns with the Finesse Rotary Microtome (Thermo Shandon, Cheshire, UK), and stained with 
haematoxylin and eosin using Leica autostainer XL (leica Microsystems, Wussloch, Germany).  
Sections were examined using Leitz Dialux 20EB light microscope (ENST Leitz GmbH, Wetzlar, 
Germany). Images were captured at X200 and X400 magnifications using Aperio Scanscope AT 
(Aperio, California, USA) 
 
2.3 STATISTICAL ANALYSIS 
In the in vivo study, statisticians worked to allow a 2-fold change in mean from vehicle to be 
detected with reasonable levels of certainty (80% power). To achieve this, the number of 
animals per group was 5 except in the control group of the HRN™ mice due to the limited 
number of animals. For all data, statistical analysis was done using the statistical function on 
Microsoft
®
 Office Excel. Analysis was carried out using Student t-test and values p<0.05 were 
considered significant. 
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CHAPTER THREE 
 
3.0  RESULTS 
 
3.1  IN VITRO STUDY 
 
3.1.1  NADPH-Cytochrome c Reductase Assay 
Figure 3.1 below shows the activity of NADPH-Cytochrome c reductase in liver microsomes 
from dog, HRN™ and C57BL6J mice. The C57BL6J mouse was shown to manifest the highest 
level of the functional CYP activity, whilst the lowest activity was found in the HRN™ mouse. 
Enzyme levels in dog liver microsomes might indicate a species difference or be due to 
prolonged storage of the dog liver. 
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Fig 3.1: Comparison of NADPH-Cytochrome c reductase activity in liver microsomes from HRNTM and 
C57BL6J mice and the dog. 
 Data presented are Mean±SD 
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3.1. 2   Succinate Dehydrogenase (SDH) Assay in Mitochondrial Pellets 
 
SDH is a marker enzyme of mitochondria (Graham 2002). Mitochondria pellets from dog, 
HRN™ and wild-type (C57BL6J) mice were assayed for SDH activity. Succinate dehydrogenase 
levels were highest both in the light and heavy mitochondrial pellets of HRN mice while dog 
and the wild-type mice showed a lower level of this enzyme (Figure 3.2). 
 
 
 
 
3.1.3  Covalent Binding of [14C]-Diclofenac 
 
This assay measured the covalent binding of reactive metabolites with liver microsomal 
proteins. NADPH- and UDPGA-dependent metabolism of 14C-diclofenac resulted in the 
highest covalent binding with dog liver microsomes. When compared with the incubation 
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Fig 3.2: Succinate Dehydrogenase activity in light and heavy mitochondrial fractions obtained from 
HRNTM and C57BL6J mice and the dog livers: It measured change in absorbance (at 500nm 
wavelength) resulting from reduction of cytochrome c in the biological sample in the presence of 
cyanide.  LM: Light mitochondrial Pellets; HM: heavy Mitochondrial Pellets. 
Data presented as Mean±SD, n=4 (HM), n=3 (LM, dog), n=2 (LM, C57BL6J & HRN)  
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without NADPH after 60 minutes, there was a significant (p<0.05) increase in covalent binding 
in the presence of NADPH (figure 3.3). However, in the presence of the CYP inhibitor, ABT (1-
amino benzotriazole), covalent binding was significantly (p<0.05) decreased.  The same trend is 
true for C57BL6J mouse liver microsomes. On the other hand, HRN™ liver microsomes did not 
manifest any significant change in the covalent binding in the presence of NADPH.  
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Fig 3.3: Covalent binding in liver microsomes incubated with 14C-diclofenac: HRN, C57BL6J mouse and dog 
liver microsomes were incubated with 14C-diclofenac in the presence of co-factors (NADPH or UDPGA) for 
60 minutes. Proteins were harvested, protein assayed and radioactivity measured. 
WT: C57BL6J mouse, Mic=microsomes, Mic-NADPH=microsomal incubation without NADPH. 
NADPH=nicotinamide adenine dinucleotide phosphate, ABT=1-amino benzotriazole. UDPGA=Uridine 
diphosphate glucuronic acid. BA: back added. Data was analysed using Student’s t-test, followed by one-way 
analysis of variance. * Significantly different from background (Mic + NADPH, T=0) at p<0.05, ** significantly 
different from background (Mic + NADPH, T=0) at p<0.01., # significantly different from CVB in incubations 
without inhibitor (Mic+NADPH, T=60). 
Data are Mean±SD; n=3.  
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3.1.4   Covalent Binding of [14C]-Fenclozic acid 
 
After 60 minutes of incubation, NADPH-dependent covalent binding was significantly (p<0.05) 
higher in dog and C57BL6J mouse liver microsomal incubations when compared with those 
without NADPH. ABT significantly (p<0.05) reduced the covalent binding in dog and  C57BL6J 
mouse liver microsomal incubations after 60 minutes, with no significant effect on HRN mouse 
liver microsomes. Although the increase in CVB in the HRN™ mouse liver microsome in the 
presence of NADPH was significant, the effect could not be said to be NADPH-dependent as it 
was sustained in the presence of ABT. There was no covalent binding in the presence of 
UDPGA in all three microsomal incubations as values were lower than those for the back added 
samples (Figure 3.4). 
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Fig 3.4: Covalent binding in liver microsomes incubated with 14C-fenclozic acid: HRN, C57BL6J mouse and dog 
liver microsomes were incubated with 14C-fenclozic acid in the presence of co-factors (NADPH or UDPGA) for 
60 minutes. Proteins were harvested, protein assayed and radioactivity measured. 
WT: C57BL6J mouse, Mic=microsomes, Mic-NADPH=microsomal incubation without NADPH. 
NADPH=nicotinamide adenine dinucleotide phosphate, ABT=1-amino benzotriazole. UDPGA=Uridine diphosphate 
glucuronic acid.  BA: back added. Data was analysed using Student’s t-test, followed by one-way analysis of 
variance. * Significantly different from background (Mic + NADPH, T=0) at p<0.05, ** Significantly different 
from background (Mic + NADPH, T=0) at p<0.01., # Significantly different from CVB in without inhibitor 
(Mic+NADPH, T=60).  
Data are Mean±SD; n=3.  
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3.1.5   Metabolism of [14C]-Diclofenac in Microsomal Incubations 
 
Table 3.1, figures 3.5 and 3.6 shows the different metabolic patterns in the HRN™, wild-type 
and dog liver microsomes. In the presence of NADPH, there was minimal oxidative metabolism 
produced in HRN™ liver microsomes, indicating negligible CYP activity, whereas in the wild-
type mouse, these metabolites (M1, M2 and M3). Dog and HRN™ mouse liver microsomes 
produced M4. In the presence of UDPGA, a similar metabolite pattern was observed in all 
three microsomes indicated by UDP-glucuronosyltransferase activity to glucuronides (M5, M6 
and M7) (figure 3.6). The peak area of M4 was higher in dog liver than in HRN™ mouse or wild-
type mouse liver.   
 
Peak 
ID 
tR (min) Assignment [M-H]
- (predominant 
35Cl2/
14C1 
isotope) 
Elemental 
Composition 
[M-H]- 
P 42.4 [14C]-Diclofenac 296.0123 C13
14C1H10O2N1Cl2 
M1 25.8 Mono-hydroxy, ketone 
oxidation 
325.9866 C13
14C1H8O4N1Cl2 
M2 28.9 4’-hydroxy 312.0073 C13
14C1H10O3N1Cl2 
M3 31.4 5-hydroxy 312.0073 C13
14C1H10O3N1Cl2 
M4 38.6 Ketone oxidation 309.9916 C13
14C1H8O3N1Cl2 
M5 39.3 1-β-O-acyl glucuronide 472.0442 C19
14C1H18O8N1Cl2 
M6 42.2 Transacylated 
acylglucuronide 
472.0441 C19
14C1H18O8N1Cl2 
M7 42.9 Transacylated 
acylglucuronide 
472.0443 C19
14C1H18O8N1Cl2 
     
tR – retention time 
 
Table 3.1: Summary of mass spectrometric data and assignment of selected [14C]-diclofenac-derived metabolites 
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Fig: 3.5: Radio chromatogram of in vitro metabolism of [14C]-diclofenac in HRN™, WT or Dog liver    
microsome in the presence of NADPH. 
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Fig: 3.6: Radio chromatogram of in vitro metabolism of [14C]-diclofenac in HRN™, WT or Dog liver microsome in 
the presence of UDPGA 
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3.2  IN VIVO STUDY 
 
3.2.1  Dose-Range Finding Study in C57BL6J mice 
 
3.2.1.1  Effect of diclofenac or fenclozic acid on body weight of C57BL6J mice 
 
Table 3.2 below shows the percentage change in daily body weight of C57BL6J mice after oral 
administration of the test drugs. In all the groups, there was a decrease in body weight, with 
the mice treated with 100 mg/kg fenclozic acid exhibiting the highest decrease.  However, at 
the end of the study, there was a net weight gain in all groups, except the 100 mg/kg fenclozic  
acid. 
 
 
 Body weight (mg)  
Percentage change in body weight relative to day 1(%) 
day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 
 
Control 
 
22.82 
 (0) 
22.44 
(-1.67) 
22.92 
(-0.44) 
22.62 
(-0.88) 
22.72 
(-0.44) 
23 
(0.79) 
23.2 
(1.67) 
23.68 
(3.77) 
 
DFC 10 
mg/kg 
 
23.26 
(0) 
23.06 
(0.86) 
23.26 
(0) 
23.5 
(1.03) 
23.52 
(1.12) 
23.68 
(1.81) 
23.7 
(1.89) 
23.18 
(3.96) 
 
DFC 
20mg/kg 
 
23.16 
(0) 
22.98 
(-0.78) 
23.38 
(0.95) 
23.38 
(0.05) 
23.46 
(1.30) 
23.34 
(0.78) 
23.42 
(1.12) 
23.68 
(2.25) 
 
DFC 
30mg/kg 
 
23.44 
(0) 
23.32 
(-0.51) 
23.4 
(-0.77) 
23.26 
(-0.77) 
23.6 
(0.68) 
23.94 
(2.13) 
23.42 
(-0.9) 
23.48 
(0.17) 
 
FA 50mg/kg 
 
23.6 
(0) 
22.98 
(-2.63) 
23.44 
(-2.37) 
23.04 
(-2.37) 
23.38 
(-0.93) 
23.52 
(-0.34) 
23.52 
(-0.34) 
23.96 
(1.53) 
 
FA 
100mg/kg 
 
23.18 
(0) 
22.34 
(-3.62) 
22.66 
(-2.67) 
22.56 
(-2.67) 
22.86 
(-1.38) 
23.32 
(0.60) 
23.04 
(-0.60) 
23.16 
(-0.09) 
Table 3.2: Effect of oral administration of diclofenac or fenclozic acid on daily body weight of C57BL6J mice. Mice 
were orally administered diclofenac or fenclozic acid and body weight was taken each day of treatment. The table 
below show percentage change in body weight each day of treatment. DFC=diclofenac, FA=Fenclozic acid. Values in 
parentheses represent percentage change in body weight relative to day 1 of study. 
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3.2.1.2 Liver-to-body weight ratio in C57BL6J mice treated with diclofenac or fenclozic 
acid 
 
There was a significant (p<0.05) increase in liver-to-body weight ratio in the C57BL6J mice 
treated with 20 mg/kg DFC and 100mg/kg FA when compared with control animals (Figure 
3.7). All livers appeared normal on visual examination, while the spleen of one of the mice in 
the group treated with 100 mg/kg FA was slightly discoloured.  
 
 
 
 
 
 
 
3.2.1.3 Time-dependent change in ALT levels in C57BL6J mice treated with diclofenac 
or fenclozic acid 
 
Figure 3.8 shows time-dependent effect of the oral administration of diclofenac or fenclozic 
acid on plasma alanine aminotransferase (ALT) in C57BL6J mice.  When compared with control 
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Fig 3.7:  Liver-to-body-weight ratio in C57BL6J mice treated with diclofenac or fenclozic acid:  
Mice were orally dosed diclofenac or fenclozic acid daily for 7 days. On day 8 mice were necropsied and 
the liver was visually observed for abnormality. Livers were weighed and the liver-to-body-weight ratio 
was determined by dividing the weight of the liver by the weight of the individual mouse on termination.  
Data was analysed using Student’s t-test, followed by one-way analysis of variance. n=5; data presented as 
Mean ± SEM; *significantly different from control at p<0.05.  DFC: diclofenac; FA=fenclozic acid 
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values, ALT levels in mice treated with diclofenac and fenclozic acid at 50 mg/kg exhibited no 
evidence of alterations. However, elevated ALT values were observed at day 8 after daily 
administration of fenclozic acid at 100 mg/kg.  
 
  
 
 
 
 
 
 
3.2.1.4  Biochemical parameters in C57BL6J mice treated with diclofenac or fenclozic 
acid 
 
                                  At the end of the dose-range finding study, no significant difference in aspartate 
aminotransferase (AST) levels were observed between the dosed and control groups. However, 
there was a significant (p<0.05) increase in ALT level in the group that received 100 mg/kg FA 
when compared with the control. A dose dependent, significant (p<0.05) decrease in the level 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
Day -1 Day 2 Day 4 Day 8 
A
LT
 L
e
ve
l (
IU
/l
) 
CONTROL 
DFC 
(10mg/kg) 
DFC (20 
mg/kg) 
DFC (30 
mg/kg) 
FA (50mg/kg) 
FA (100 
mg/kg 
Fig 3.8: Time-dependent change plasma in ALT levels in C57BL6J mice treated with diclofenac 
or fenclozic acid.  Blood was taken from mice by tail veil bleeding on days -1, 2 and 4 of the 
study. Also, at the end of the study (day 8), blood was obtained by cardiac puncture via the vena 
cava. In both cases, blood was centrifuged and resultant plasma was assayed for ALT (alanine 
aminotransferase) as described in methods. Data was analysed using Student’s t-test, followed by 
one-way analysis of variance. n=5; data presented as Mean ± SD; * significantly different from value on 
day -1 at p<0.01.  DFC: diclofenac; FA=fenclozic acid 
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of plasma alkaline phosphatase was observed at 20- and 30 mg/kg diclofenac, while the 
activity of plasma glutamate dehydrogenase was significantly decreased at 30mg/kg 
diclofenac (Figure 3.9).  
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Fig. 3.9: Effect of diclofenac or fenclozic acid on AST, ALT, GLDH and ALP levels in C57BL6J mice  
Mice were orally dosed diclofenac or fenclozic acid daily for 7 days. On day 8 mice were necropsied and 
blood taken via the vena cava, centrifuged and resultant plasma auto analysed for various biochemical 
parameters shown above. Data was analysed using Student’s t-test, followed by one-way analysis of 
variance.. n=5; data presented as Mean ± SEM; * significantly different from the control group, p<0.05. DFC: 
diclofenac; FA=fenclozic acid 
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3.2.2  HRNTM STUDY 
 
3.2.2.1  Effect of diclofenac or fenclozic acid on body weight of HRNTM mice 
A slight decrease in body weight was observed in the control HRNTM group until day 5 of the 
study. Thereafter the body weights returned to pre-dose or slightly above pre-dose values 
(Table 3.2).    A small decrease in body weight was also observed in those animals administered 
with diclofenac and a greater effect in those mice administered with fenclozic acid. In both 
cases the weight remained below the pre-dose body weight for the duration of the study 
(Table 3.2). The decrease in body weight did not exceed the severity limit of the licence. 
 
 
 
 
 
 
 
 
  Body weight (mg) 
Percentage change in body weight relative to day 1(%) 
day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 
 
         Control 22.6 
(0) 
 
    22.1 
(-0.44) 
 
22.5 
(-0.44) 
 
22.28 
(-1.44) 
 
22.25 
(-1.55) 
 
22.6 
(0) 
 
22.88 
(1.22) 
 
22.7 
(0.44) 
 
DFC  30mg/kg 
 
23.12 
(0) 
 
22.74 
(-1.64) 
 
22.74 
(-1.12) 
 
22.56 
(-2.42) 
 
22.94 
(-0.78) 
 
22.8 
(-1.38) 
 
22.78 
(-1.47) 
 
22.7 
(-1.82) 
 
FA 100mg/kg 23.18 
(0) 
22.2 
(-4.32) 
22.14 
(-4.49) 
21.92 
(-5.44) 
22.28 
(-3.88) 
22.54 
(-2.76) 
22.68 
(-2.16) 
22.68 
(-2.16) 
Table 3.3:  Effect of oral administration of diclofenac or fenclozic acid on daily body weight of HRN™ mice. 
Mice were orally administered diclofenac or fenclozic acid and body weight was taken each day of treatment. 
The table below show percentage change in body weight each day of treatment. DFC=diclofenac, FA=Fenclozic 
acid. Values in parentheses represent percentage change in body weight relative to day 1 of study. 
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3.2.2.2 The effect of diclofenac and fenclozic acid on the liver-to-body weight ratio in 
HRNTM mice  
 
No significant changes in the liver-to-body weight ratio were observed in the HRNTM mice 
dosed with 30 mg/kg DCF for 7 days when compared with the control animals. An apparent 
increase in liver-to-body-weight ratio was observed in the group treated with 100mg/kg FA, 
although this did not achieve statistical significance (Figure 3.10). 
 
 
 
3.2.2.3 Time-dependent change in ALT levels in HRNTM mice treated with diclofenac or 
fenclozic acid 
 
In all animals, the mean plasma ALT values prior to dosing were high, when compared with 
wild-type mice. The mean plasma ALT values for the control group increased throughout the 
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Fig 3.10:  Liver-to-body-weight ratio in HRN™ mice treated with diclofenac or fenclozic acid: 
Mice were orally dosed diclofenac or fenclozic acid daily for 7 days. On day 8 mice were necropsied and 
the liver was visually observed for abnormality. It was weighed and the liver-to-body-weight ratio was 
determined by dividing the weight of the liver by the weight of the individual mouse on termination.  
Data was analysed using Student’s t-test, followed by one-way analysis of variance. n=5 for DFC and FA 
groups, while n=4 in the control group; data presented as Mean ± SEM; * significantly different from 
control at p<0.05 
DFC: diclofenac; FA=fenclozic acid 
 
 
 
 
 
47 
 
duration of the study, while in the group receiving 100 mg/kg FA or 30 mg/kg DFC, ALT values 
were very similar throughout the study (Figure 3.11).  
  
 
 
 
 
 
3.2.2.4 The effect of diclofenac or fenclozic acid on clinical chemistry parameters in 
HRNTM mice  
 
Markedly significant decreases in the mean levels of bilirubin (p<0.01), ALP (p<0.01), bile acid 
(p<0.05) and GLDH (p<0.05) levels were observed in HRNTM mice administered with 30 mg/kg 
DFC and 100 mg/kg FA for 7 days. In addition, highly significant (p<0.01) reductions in mean 
ALT levels and a significant (p<0.05) decrease in total protein, albumin and AST levels were 
observed in the group dosed with 30 mg/kg DFC. There were also non-statistically significant 
decreases in the level of cholesterol in the treated groups in comparison with the control 
(Figures 3.12 a & b). The ALT, AST, ALP and GLDH values were high when compared with the 
wild-type mice. 
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Fig 3.11: Time-dependent change in ALT levels in HRNTM mice exposed to diclofenac or fenclozic acid for 
7 days.  Blood was taken from the mice by tail veil bleeding on days -1, 2 and 4 of the study. Also, at the 
end of the study (day 8), blood was obtained by cardiac puncture via the vena cava. In both cases, blood 
was centrifuged and resultant plasma was assayed for ALT (alanine aminotransferase) as described in the 
methods. Data was analysed using Student’s t-test, followed by one-way analysis of variance. Data are 
mean values; n=5 for DFC and FA groups, while n=4 in the control group. DFC: diclofenac; FA=fenclozic 
acid 
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Fig 3.12a: Some biochemical parameters in HRN™ mice treated with diclofenac or fenclozic acid:  
Mice were orally dosed diclofenac or fenclozic acid daily for 7 days. On day 8, mice were necropsied and 
blood taken via the vena cava, centrifuged and resultant plasma auto analysed for various biochemical 
parameters shown above..  Data was analysed using Student’s t-test, followed by one-way analysis of 
variance. n=5 for DFC and FA groups, while n=4 in the control group; data presented as Mean ± SEM; * 
significantly different from control at p<0.05. ** Significantly different from control at p<0.01. DFC: 
diclofenac; FA=fenclozic acid 
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Fig 3.12b:  Some biochemical parameters in HRN™ mice treated with diclofenac or fenclozic acid:  
Mice were orally dosed diclofenac or fenclozic acid daily for 7 days. On day 8, mice were necropsied and 
blood taken via the vena cava, centrifuged and resultant plasma auto analysed for various biochemical 
parameters shown above Data was analysed using Student’s t-test, followed by one-way analysis of 
variance. n=5 for DFC and FA groups, while n=4 in the control group; data presented as Mean ± SEM; 
*significantly different from control at p<0.05. DFC: diclofenac; FA=fenclozic acid 
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3.3 Histopathology of livers of C57BL6J and HRN™ mice treated with diclofenac 
and fenclozic acid 
 
Table 3.3 and figure 3.13 report the histological changes in livers of C57BL6J and HRN™ mice 
treated with diclofenac and fenclozic acid. In figure 3.13, plate A shows mild hepatocyte 
necrosis with inflammatory cell infiltration and inflammatory cell aggregates in vehicle 
control-treated C57BL6J mice, while treatment with diclofenac resulted in reduced hepatocyte 
vacuolation, mild hepatocyte necrosis, mild hepatic necrosis and mixed inflammatory cell 
aggregation. However, fenclozic acid (E) caused a reduced centrilobular hepatic vacuolation 
and mixed inflammatory cell aggregates. Vehicle-control-treated HRN™ mice (B) showed a 
mild hepatocellular fat vacuolation, severe bile duct proliferation, periportal hepatocyte 
necrosis and mild hepatocyte necrosis with inflammatory cell infiltration. In the diclofenac and 
fenclozic-acid-treated HRN™ mice (D&F), there was a reduction in the incidence and severity 
of hepatocellular fat vacuolation and centrilobular hepatic vacuolation, while only diclofenac 
(D) showed a reduced periportal hepatocyte necrosis and inflammatory cell infiltration. On the 
other hand, diclofenac and fenclozic acid (D&F) resulted in an increase in incidence and 
severity of hepatocyte necrosis with inflammatory cell infiltration. 
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Group 1: CONTROL; Group 2: 10 mg/kg/day Diclofenac; Group 3: 20 mg/kg/day Diclofenac; Group 4: 30 mg/kg/day 
Diclofenac; 
Group 5: 50 mg/kg/day Fenclozic acid; Group 6: 100 mg/kg/day Fenclozic acid (C57BL6J mice) 
Group 7: CONTROL; Group 8: 30 mg/kg/day Diclofenac; Group 9: 100 mg/kg/day Fenclozic acid (HRN mice) 
 
 
 
 
 
 
 Dose group       1 2 3 4 5 6 7 8 9 
                                                            no of animals  5 5 5 5 5 5 4 5 5 
      No examined            5 5 5 5 5 5 4 5 5 
  Finding                                      N.A.D. : 2 1 1 2 2 1 - - - 
- hepatocellular fat vacuolation. : - - - - - - 4 5 5 
Grade 2. . . . . . . . . : - - - - - - - 4 - 
Grade 3. . . . . . . . . : - - - - - - 4 1 4 
Grade 4. . . . . . . . . 
 
: - - - - - - - - 1 
- multifocal hepatocellular necrosis : - - - - - - 1 1 1 
Grade 2. . . . . . . . . 
 
: - - - - - - 1 1 1 
- bile duct proliferation . . . . : - - - - - - 4 5 5 
Grade 1. . . . . . . . . . . . : - - - - - - - - 2 
Grade 2. . . . . . . . . . . . : - - - - - - 1 4 1 
Grade 3. . . . . . . . . . . . 
 
: - - - - - - 3 1 2 
- periportal hepatocyte necrosis/inflamm cell 
infiltration 
: - - - - - - 4 5 4 
Grade 1. . . . . . . . . . . . . : - - - - - - - 4 3 
Grade 2. . . . . . . . . . . . . 
 
: - - - - - - 4 1 1 
           
- reduced centrilobular hepatocyte vacuolation . : - - - 3 1 1 - - - 
Grade 1. . . . . . . . . . . . . : - - - - 1 - - - - 
Grade 2. . . . . . . . . . . . . : - - - 3 - 1 - - - 
           
- increased hepatocyte vacuolation . . . . . : - 2 4 - - - - - - 
Grade 2. . . . . . . . . . . . . : - 1 4 - - - - - - 
Grade 3. . . . . . . . . . . . . : - 1 - - - - - - - 
           
           
- hepatocyte necrosis with inflammatory cell 
infiltration 
: 1 1 - - - - 2 3 5 
Grade 1. . . . . . . . . : 1 1 - - - - 2 3 4 
Grade 2. . . . . . . . . : - - - - - - - - 1 
           
- mixed inflammatory cell aggregates : 2 3 1 1 3 3 - - - 
Grade 1. . . . . . . . . 
 
: 2 3 1 1 3 3 - - - 
Table 3.4: Pathology report on the effect of oral administration of Diclofenac and fenclozic acid on livers of 
C57BL6J and HRN mice: Mice were orally administered diclofenac or fenclozic acid for 7 days. On day 8, 
animals were necropsied, liver sections taken, stained with haematoxylin and eosin, and viewed under a light 
microscope 
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     (A)                                                             VEHICLE CONTROL                                                                               (B) 
              
C57BL6J              HRN  
 
 
   (C)      DICLOFENAC-DOSED      (D) 
               
C57BL6J                                        HRN  
 
 
   (E)               FENCLOZIC-ACID-DOSED                     (F) 
                
C57BL6J              HRN  
 
 
 
 
 
 
Fig 3.13: Representative photomicrographs of livers from C57BL6J mice dosed with diclofenac or fenclozic 
acid.  Mice were necropsied, liver sections taken and stained with haematoxylin and eosin. Slides were 
viewed under original objective lens of X20 magnification.  Images illustrate hepatocellular appearances in 
centrilobular (green arrows) to periportal regions (yellow arrows).  
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CHAPTER FOUR 
 
4.0  DISCUSSION 
4.1  Succinate dehydrogenase and NADPH-Cytochrome c Reductase Assays 
 
When organelles are isolated, there is need for sensitive and robust assays to detect their 
presence. The usual approach is to test for the activity of an enzyme (marker enzyme), known 
to be solely localised in the organelle. For example, succinate dehydrogenase (SDH) is found in 
the mitochondrion, while cytochrome c reductase is localised on the smooth endoplasmic 
reticulum (Graham, 2002). Marker enzymes are very useful in monitoring the cell fractionation 
process. In addition, biochemical purity of the isolated organelles can be determined using the 
marker enzyme, such that the presence of an undesired marker enzyme in a fraction indicates 
impurity.  On the other hand, specific activity of the marker enzyme shows the level of 
enrichment of the isolate with the organelle of interest (Padh, 1992). Otherwise known as 
complex II, succinate dehydrogenase (SDH) is an inner membrane-bound enzyme complex. It 
is the only mitochondrial enzyme involved both in Krebs cycle and oxidative phosphorylation 
(Cimen et al. 2010). It is central to complex II of the electron transport chain, a process crucial 
to mitochondrial energy generation.  In addition to this, SDH, in conjunction with ubiquinone, 
has been reported to be an important antioxidant enzyme in the mitochondria that moderates 
superoxide scavenging activity of the respiratory chain (Hajjawi, 2011). Hence, determining its 
activity in the mitochondrial pellets helps to know the state of the mitochondrion and hence 
the liver from which it was obtained. The light mitochondrial pellets contain the mitochondrion 
and some contaminants, including lysosomes, peroxisomes, Golgi membranes, and some 
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endoplasmic reticulum. The heavy mitochondrial pellets predominantly contain the 
mitochondria and very few contaminants which are removed by repeated washing. It is the 
main source of mitochondria used for respiratory studies (Graham, 2002). This explains the 
relatively higher SDH value in the heavy mitochondrial pellets (Figure 3.2). NADPH-
cytochrome c reductase is a flavoprotein localised to the smooth endoplasmic reticulum (SER). 
It transfers electrons from NADPH to several oxygenases, the most important of which is the 
cytochrome P450 family of enzymes. Induction of cytochrome c reductase, similar to CYPs, 
causes proliferation of the SER (Thaler et al., 1972). Hence, its activity is an indirect estimation 
of the state of the SER, CYPs and hence the metabolic competence of the microsomal 
preparation it is assayed in. In this experiment, its value in the microsomal preparation from the 
C57BL6J mouse was within the range previously reported in literature (Williams and 
Woodhouse, 1995).  The HRN™ mouse has been genetically modified to be deficient in the 
POR gene. Markedly low NADPH-Cytochrome c reductase activity is expected in microsomes 
prepared from HRN™ mice when compared to those from the C57BL6J mouse liver 
microsomes. The level in the dog liver microsome was lower than that in the C57BL6J mouse 
(Figure 3.1). An explanation for this can be seen in a study where preservation of human liver 
microsomes at -80°C was reported to cause about 40% reduction in CYP and cytochrome c 
reductase activities (Pearce et al., 1996). Similarly, the relatively low value of this enzyme in the 
dog liver microsome might be attributed to the duration of the storage of the liver. Despite the 
slightly low values recorded for the values of the enzyme, there is strong evidence that the 
livers were viable, as observed in subsequent assays carried out on them (figures 3.3 and 3.4).  
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4.2 Covalent Binding (CVB) assay in Dog, C57BL6J and HRN™ Mouse Liver 
Microsomes 
 
The covalent binding assay is an in vitro assessment of the potential of a xenobiotic to be bio-
activated to chemically reactive metabolites, which form adducts with essential cellular 
macromolecules (Obach et al., 2008). The pharmaceutical industry has employed this assay as 
one of the battery of tests carried out on candidate drugs in early prediction of toxicity and 
idiosyncratic adverse drug reactions (IADR). Data obtained with [14C]-Diclofenac 
demonstrated significantly increased NADPH-dependent CVB in dog liver microsomes 
(p<0.01) and wild-type mouse (C57BL6J) liver microsomes (p<0.05) after 60 minutes of 
incubation. On the other hand, NADPH-dependent CVB in the HRN™ mouse liver microsomes 
was at background levels. This supports literature data that HRN™ mice, which are deficient in 
functional CYP activity, do not participate in phase I drug metabolism (Henderson et al., 2003; 
Pickup et al., 2012). NADPH-dependent CVB indicates the formation of CYP-mediated 
reactive metabolites that covalently interact with cellular contents (Obach et al., 2008). 
Diclofenac is oxidatively metabolised by CYPs 2C8, -2C9 and -3A4. CYP3A4 biotransforms 
diclofenac to its 5-OH metabolite and can be further metabolised to a p-benzoquinone imine 
which is thiol-reactive, and which can also be involved in redox cycling, culminating in 
oxidative stress. Alternatively, the phenylamine ring can be oxidised to form an epoxide. Both 
metabolites are electrophilic and can react with protein and non-protein thiol components of 
the cell. On one hand, it can result in the depletion of glutathione with consequent oxidative 
stress and potential cell damage. The epoxide formed can also covalently bind with and 
inactivate enzymes (Boelsterli, 2003), further strengthening the involvement of CYP in the CVB 
of diclofenac and its metabolite.  UDPGA-dependent covalent binding is an indication of UGT-
mediated metabolism. As mentioned in the introduction, the resulting acyl glucuronides can 
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potentially react with thiol group on cellular protein. Results after 60-minute incubation time 
showed that the CVB value in the HRN™ mouse liver microsomes was slightly higher than in the 
wild-type. Dog liver microsome recorded the highest CVB values. This observation might 
support studies that showed dogs to have a higher (ten-fold) capacity for glucuronidation than 
humans (Soars et al., 2001).  
Similar to the results obtained for [14C]-Diclofenac, the NADPH-dependent covalent binding 
of [14C]-fenclozic acid to HRN™ mouse liver protein were at background levels and was much 
lower than what was obtained for dog or wild-type liver microsomes. Once again, this is an 
indication of a low CYP-mediated metabolism in the HRN™ mice. It also shows that in the 
presence of NADPH, fenclozic acid strongly forms a highly reactive metabolite in dog and 
wild-type mice (about 5- and 2 fold higher than in HRN™). In the presence of 1–
aminobenzotriazole (ABT), a CYP inhibitor, this CVB was highly reduced to near background 
levels. CVB in HRN™ mouse liver microsome remained unchanged in the presence of ABT. On 
the other hand there was no CVB in the presence of UDPGA in all the groups. These fenclozic 
acid data are in agreement with previous studies carried out in AstraZeneca (unpublished), 
using human, dog and rat liver microsomes. One study showed a high CVB in the presence of 
NADPH after 60 minutes but near background levels in the presence of UDPGA over the same 
time period. When the microsomal preparations were further incubated with recombinant 
flavin monooxygenases (FMO3 and FMO 5), covalent binding remained at background level. 
An in vivo metabolism study on fenclozic acid carried out in AstraZeneca (unpublished) lends 
support to this as in vivo metabolites in B57BL6J mice constituted mainly of epoxides of the 
parents compounds. As earlier mentioned, epoxides are highly-reactive metabolites.   These 
data and results from the current experiments might indicate that the reported fenclozic acid 
toxicity in humans could be related to CYP-mediated metabolism (Hart et al., 1970). Also, the 
possession of a carboxylic acid moiety does not automatically indicate a compound would 
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produce a reactive acyl glucuronide. However, this functional group only serves as a structural 
alert for potential toxicity (Skoberg et al., 2008). Further, in vitro CVB does not always translate 
to toxicity in vivo. This was illustrated in a study by Obach et al. (2008), in which nine known 
hepatotoxic and nine known non-hepatotoxic drugs were assessed for CVB in human liver 
microsomes. There was CVB in seven of each group of drugs, with paroxetine, a non-
hepatotoxic drug showing the highest amount of CVB. Therefore, while CVB to certain cellular 
proteins might be indicative of toxicity, CVB to others might not. It has been reported that 
binding to certain proteins could be protective as that might be involved in the inactivation of 
reactive electrophiles (Moro et al., 2012). The protein target involved is very crucial. This 
emphasises the value of other investigative studies including in vivo toxicological studies to 
fully confirm observations made.  
 
4.3 In vitro Metabolism of [14C]-Diclofenac in dog, wild-type and HRN™ mouse 
liver microsomes 
 
The data shown in the Table 3.1, figures 3.5 and 3.6 are mass spectrometric data and 
radiochromatograms indicating the formation of metabolites in the presence of the respective 
co-factors. In the HRN liver microsomes supplemented with NADPH, the formation of very low 
peaks for 4’- and 5-hydroxy diclofenac indicates little or no CYP-mediated metabolism taking 
place. This further verifies that the HRN liver lacks functional CYP activity. This is in contrast to 
the wild-type mouse liver microsomes, in which there were high levels of hydroxylated 
metabolites. UDPGA-dependent metabolites were detected in all three microsomal 
incubations, with the dog having the strongest peak value for the 1-β-O-acyl glucuronide. This 
correlates well with the highest UDPGA-dependent CVB in dog liver microsomal incubations. 
Also, the peak values for 1-β-O-acyl glucuronide in both mouse strains had comparable peak 
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values on the radiochromatograms. It also parallels the CVB values for both strains in which 
there was no observable difference. These data show that CVB of diclofenac in the liver 
microsomal incubations studied were related to the metabolism of the parent compound. In 
addition to the formation of protein adducts, reactive metabolites of diclofenac have potential 
to induce mitochondrial injury, ATP depletion resulting in necrosis or apoptosis. Gómez-
Lechón et al. (2003a and 2003b) demonstrated cytotoxicity of diclofenac and its 5OH and 
4’OH metabolites on rat and human liver hepatocytes, and reported an induction of apoptotic 
cell damage via opening of the membrane permeability transition (MPT) pore and activation of 
caspases 3, 8 and 9. This further confirms the role played by metabolism of diclofenac in its 
hepatotoxicity.   
 
 
4.4  In vivo Studies in C57BL6J and HRN™ Mice 
 
These studies were designed to investigate the utility of the HRN™ mice in understating the 
role of conjugative metabolism of carboxylic-acid-containing drugs, with diclofenac and 
fenclozic acid as a case study. It was a follow up on previous studies carried out at AstraZeneca 
R&D, UK, which revealed that the HRN™ mouse had clearly different pharmacokinetic profile 
from its wild-type counterpart (Pickup et al, 2012; Sarda et al., 2012).  The dose-range-finding 
(DRF) study was a pilot study designed to test the tolerable limit of the drug in the wild-type 
strain, while the highest tolerable dose would subsequently be used in the HRN™ mouse study. 
The highest doses in the study (30 mg/kg/day diclofenac and 100 mg/kg/day fenclozic acid) 
produced no adverse effect up to the severity limit of the approved Home Office licence for 
the study. There was also no mortality in any groups throughout the study and no clinical signs 
of concerning levels of overt compound toxicity. 
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4.4.1 Effect of diclofenac or fenclozic acid on body weight of C57BL6J and HRN™   
mice 
     In the DRF and HRN™ studies, there was loss in body weight among all the groups. This 
might not appear to be compound-related as the control groups lost 1.67% and 2.21% body 
weight in the DRF and HRN™ studies respectively (Tables 3.1 and 3.2). In some cases, the 
weight losses in the control groups were higher than in the groups of mice dosed with the test 
drugs. There was recovery from day 6 of study in the control groups in both studies. While this 
effect might be due to either animal handling or effect of blood collection, higher doses of 
fenclozic acid resulted in the highest loss in body weight in both studies. This observation 
might be due to fenclozic-acid-related toxicity. 
 
 
4.4.2  Effect of diclofenac or fenclozic acid on Liver-to-body-weight ratio    
in C57BL6J and HRN™   mice  
 
Changes in organ weight and organ-to-body-weight ratio are often associated with compound 
related effects. In multidose toxicity study, organ weight measurement gives insight into the 
likely toxicodynamics and toxicokinetics of the test compound (Sellers et al., 2007). The organ-
to-body weight ratio the DRF study increased in a compound-related manner and was 
statistically significant (p<0.05) at 20 mg/kg diclofenac and 100 mg/kg fenclozic acid (Figure 
3.7) On the other hand, in the HRN™ study there were increases, but which were not 
statistically significant in the fenclozic-acid-treated group (Figure 3.10). While not statistically 
significant and might not be compound-related, a comparison with the values obtained in the 
wild-type mice gives an indication of strain-related changes in the liver weight. For example, 
while the control values of liver–to-body-weight ratios of the wild-type control and 100 mg/kg 
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fenclozic acid were 0.055 and 0.065 respectively, it was 0.108 and 0.112 in the corresponding 
HRN™ groups. A similar observation was made in a study by Henderson et al. (2003) which 
revealed that HRN™ mouse livers were enlarged, with liver-to-body-weight ratio being almost 
twice that in the wild-type mice, in addition to a pale appearance. This indicates the possibility 
of a background hepatomegaly in the HRN™ mice. Other results, to be discussed in other 
sections will further give detailed functional differences in HRN™ mice. 
 
 
4.4.3 Effect of Diclofenac or Fenclozic Acid on Clinical Chemistry Parameters of   
C57BL6J and HRN™   Mice  
 
Another aim of the DRF is to detect at least a two-fold increase in alanine aminotransferase 
(ALT), as that would be a basis for determining the occurrence of liver injury in the wild-type 
mice (Bénichou, 1990). Therefore, ALT was assayed on plasma obtained on days -1, 2, 4 and 8. 
While values remained unchanged for the control and most other treatment groups, there was 
a three-fold change in ALT values in the 100 mg/kg fenclozic acid group on day 8 of the study 
when compared to the value before the first dose. In addition, the ALT value for 100 mg/kg 
fenclozic acid at the end of the study was significantly (p<0.05) higher than in the control 
C57BL6J mice. This was accompanied by an increase in aspartate aminotransferase (AST), 
though not statistically significant. Those observations confirmed that highest doses of 
fenclozic could potentially induce liver damage. Glutamate dehydrogenase (GLDH) levels 
remained unchanged except in the 50 mg/kg fenclozic acid group in which a significant 
(p<0.05) decrease was seen. Located in the mitochondrial matrix, GLDH is an important 
enzyme involved in the production of urea and in amino acid oxidation.  It is liver-specific and 
has features that make it a good biomarker of drug-induced hepatocellular toxicity. It is a 
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specific marker of necrosis with its activity higher in the centrilobular region than in the 
periportal zone, making the release of GLDH a prominent feature of conditions associated with 
centrilobular necrosis (O'Brien et al., 2002). There was a dose-dependent decrease in ALP in 
the diclofenac-treated C57BL6J mice. Increase in ALP is a feature of hepatobiliary injury. 
However, this study indicates an opposite trend. Ramirez-Alcantara et al. (2009) reported a 
dose-dependent decrease in ALP values in diclofenac-treated C57BL6J mice after an 
intraperitoneal dose of 60 mg/kg. While not fully understood, it is thought to be linked to the 
enteropathy caused by an exposure to the NSAID because the decreases observed paralleled 
ulceration.  However, it had been earlier believed that ALP, in protecting the gut against 
lipopolysaccarides, get leaked into the blood stream during ulceration and hence disrupt 
mucosal damage (Geddes and Philpot, 2008). A decrease in this implies a compromise of this 
protective mechanism. Hence, rather than give information on the state of the liver, the 
decrease observed in ALP in the DRF may relate to the effect of diclofenac on the gut.  
 
In the HRN™ phase of the study, a different trend was observed. There was a time-dependent 
increase in ALT levels in the control group to a maximum of 2000 IU/l, while the dosed animals 
did experience mild increases followed by a decrease on the last day of study (Figure 3.8).  At 
the end of the study, levels of other enzyme were high (Figure 3.9a). The values were much 
higher than what was recorded for their wild-type counterpart in the DRF study and in the 
literature (Fernández et al., 2010). This strongly indicates background liver dysfunction in the 
HRN™ mice which might have been previously unexplored or underreported in the literature. 
However, there are clues to the possibilities of background liver insufficiency as found in early 
articles that described the HRN™ mice. In the HRN™ mice, Henderson et al. (2003) reported 
hyperlipidaemia along with a 90% decrease in bile acid in the gall bladder, 65% and 50% 
decrease in serum cholesterol and triglycerides in comparison with the wild-type mice. Also, as 
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earlier mentioned in the introduction, they reported a significant elevation in serum ALT level. 
These findings are consistent with the results obtained in this study.  In addition, there was a 
background high alkaline phosphatase (ALP) level in the HRN™ mice, which is an index of 
cholestatic liver disease and this could be linked with the low value of bile acids. HRN™ mice 
lack functional CYPs because of their lack of the P450-oxidoreductase enzyme which donates 
electron to all endoplasmic reticulum CYPs. Aside the CYPs identified in xenobiotic 
metabolism, other families and isoforms are involved in cell physiology and homeostasis.  For 
example, CYPs51, -7A, 8B, -27A and -46A are involved in cholesterol and bile acid synthesis. 
Cholesterol is a precursor in the synthesis of vitamin D, bile acids (BAs) and steroid hormones, 
all of which play important roles in normal cell function and maintenance of the integrity of the 
cell and health of the whole organism (Lorbek et al., 2012). Hence, a lack of functional hepatic 
CYPs is associated with impaired liver which makes the HRN™ strain not so suitable to study 
hepatotoxic effect of drugs. 
 
4.4.4 Effect of Diclofenac or Fenclozic Acid on Liver Histology of C57BL6J and 
HRN™   Mice  
The liver histology of the wild-type mice revealed no drastic compound-related changes. 
Hepatocyte vacuolation were observed in the groups treated with 10- and 20 mg/kg DFC. 
Rather than being a sign of toxicity, hepatocyte vacuolation has been reported to be a cellular 
adaption, which is beneficial to the host (Nayak et al., 1996). Background mild hepatocyte 
necrosis with inflammatory cell infiltration and mixed inflammatory cell aggregates were also 
observed the wild-type mice. On the other hand, background hepatocellular fat vacuolation, 
bile duct proliferation, periportal hepatocyte necrosis, reduced centrilobular hepatocyte 
vacuolation were seen in the HRN™ mice (Table 3.4 and Figure 3.13). Hepatocellular fat 
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vacuolation is a sign of fat accumulation in the hepatocytes. As noted earlier, the lack of 
functional CYPs in the HRN™ mice makes lipid metabolism inadequate and may result in high 
levels of hepatic free fatty acid. This has been reported to be associated with significant 
increase in hepatic inflammation, oxidative stress, hepatocellular apoptosis and liver injury 
(Alkhouri et al., 2009).  Other features seen in the liver histology slides confirm inflammation 
and some hepatocyte necrosis. This harmonises with a previous study in which background 
single cell necrosis and inflammation were observed in vehicle-treated HRN™ mice (Pickup et 
al., 2012). This backs up the clinical chemistry data that gives evidence of severe background 
liver damage in the HRN™ mice. A rather interesting finding from the study is that 
administration of FA and DFC reduced the incidence and severity of hepatocellular fat 
vacuolation, bile duct proliferation and inflammatory cell infiltration. Could this imply that 
NSAIDs are protective against the background liver damage in the HRN™ mice? It is 
understood that in non-alcoholic fatty liver disease, fatty acids can initiate a cascade of events 
that causes activation and nuclear translocation of NF-ĸB and production of other pro-
inflammatory cytokines. Studies have shown that suppression of this signalling pathway 
resulted in a partial protection against liver injury (Alkhouri et al., 2009).  Further, other studies 
have suggested that NSAIDs can inhibit the NF-ĸB signalling pathway so as to down-regulate 
pro-inflammatory cytokines, with a consequent inhibition of inflammation (Vaish and Sanyal, 
2011). Whether this happened in the HRN™ mice is uncertain. However, evidence from the 
clinical chemistry data—significant reduction in ALT, AST, GLDH and ALP in the DFC- and FA-
treated HRN™ mice—strongly suggest these NSAIDs may offer some anti-inflammatory 
protection to the ‘diseased’ HRN™ mouse liver. 
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CONCLUSION AND FUTURE DIRECTION 
 
The in vitro metabolism and CVB data have demonstrated generation of reactive metabolites 
of diclofenac and of fenclozic acid and, which bind covalently to liver proteins. Bioactivation of 
diclofenac was supported by CYP and UGT co-factors, while for fenclozic acid only CYP-
dependent bioactivation could be demonstrated. The HRN™ mouse provided valuable 
confirmation of the role of CYP metabolism in the bioactivation of fenclozic acid. The studies in 
wild-type mice revealed no evidence of liver pathology following treatment with either drug. 
The data obtained with HRN™ mice revealed evidence of overt liver injury in untreated 
animals. This precluded use of the animals for investigation of liver toxicity caused by 
diclofenac or fenclozic acid. An intriguing normalisation of plasma liver parameters was 
observed in HRN™ mice treated with FA and diclofenac, which raises the possibility that the 
drugs were protective. 
 
In the future, it will be valuable to identify and map the target proteins of FA and DFC 
metabolites by administering the radio-labelled compound to the study animal. Bound liver 
proteins can be characterised by electrophoresis, fluorography and mass spectrometry. Using 
bioinformatics, the cellular function of such proteins could be determined by searching such 
target proteins in databases e.g http://tpdb.medchem.ku.edu:8080/protein_database/ 
(Hanzlik et al., 2007; Moro et al., 2012). 
 
In addition, it will be useful to apply electron microscopy (EM), glutathione (GSH) 
cytochemistry and immunohistochemistry in the understanding of the precise nature of liver 
damage in the HRN™ mice.  Also, further mechanistic studies are required to elucidate 
potential mechanisms by which NSAIDs might protect against the background hepatic lesion in 
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the HRN™ mice. It will be informative to know the specific CYP isoforms responsible for 
metabolism of fenclozic acid. Since high doses of fenclozic acid caused ALT elevations on day 8 
of treatment, raising the possibility of mild liver injury, evaluation of livers from these animals 
at the electron microscopy (EM) level might be informative and is planned in the future. The 
mechanism of toxicity of fenclozic acid will also be an interesting area to investigate using in 
vitro systems.  
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APPENDIX 
APPENDIX 1 
Calculations 
A. Derivation of formula for SDH and Cytochrome c reductase activities 
The aim is to express enzyme activity in nmol/min/mg protein. 
1. Estimate the dilution factor to obtain the actual amount of 
microsomal protein present in the reaction mix in the cuvette. 
 
In this particular case (cytochrome c reductase), a 1:10 dilution of 
microsome was made up to 50 µl and prepared in a total of 1100 µl 
reaction mix. 
Hence, total volume of reaction mix= 1100 µl, 
Volume of microsomes in reaction mix=1/10 X 50 µl=5 µl. 
 
Dilution factor= volume of microsomes in reaction mix/total volume of 
reaction mix 
 
  =5/1100 = 1/220 
 
Amount of protein in the cuvette = dilution factor X protein 
concentration (mg/ml) 
  
= 1/220 X protein concentration (mg/ml)-------(i) 
 
 
2. Calculate activity of cytochrome c reductase in nmol/min 
Deriving from the standard equation of cytochrome c reductase activity: 
   
                                                          
                                      
 
Where  A500nm/min= change in absorbance per minute 
Reckoning that the enzyme volume, dilution factor and total volume of 
reaction mix have been accounted for by equation (i), then the remainder of 
the equation becomes 
    
           
                             
,  
and the unit becomes mM X  A/time (minutes)=  A /time (minutes) 
X  mmol/ 1000 ml. 
Hence, equation becomes  A/time (min) X1/21.1(mmole-1)=  A/time 
X 1/0.0211 nmol/ml,  
 
3. Hence Cytochrome c reductase in nmol/min/mg protein becomes 
 
                                     
                   
  
   
 
 
     and the unit derived becomes 
    
       
 X 
  
  
 
 
Cytochrome c redustase working formula becomes 
        
      
   protein 
concentration X dilution factor, 
 
Were dilution factor = 
                                              
                                
 
 
Protein concentration were derived from BCA assay 
 
SDH 
This derived formula holds true for the SDH activity except that the 
extinction factor = 19.7mM
-1
 and dilution factor 1/200. 
 
B. Molar radioactivity for radio isotopes used in CVB assays. 
 
   [
14
C]-diclofenac 
Specific activity = 2.12 Kbq /nmol 
1 KBq=27 nCi 
2.12 KBq=27 X 2.12 nCi 
= 57.24 nCi/nmol, or 
57.24 mCi/ mmol 
 
1 Ci = 2.22 X 10
12
 dpm 
 
1 mol= 57.24 Ci 
1 mol= 57.24 X 2.22 X 10
12
 dpm. 
 
Hence molar radioactivity (mol/dpm) = 7.8 X 10
-15 
mol/dpm 
 
The same  calculation applies for second batch of [
14
C]-
diclofenac,  specific activity of 55 mCi/mol, and [
14
C]-
fenclozic acid,  specific activity 60.5 mCi/mmol. 
 
 
 
APPENDIX 2 
BCA PROTEIN ASSAY ON MICROSOMES AND MITOCHONDRIAL PELLETS. 
Plate layout.             
 1 2 3 4 5 6 7 8 9 10 11 12   
A 0.3
89 
0.2
69 
0.1
98 
3.011 0.685 0.377 1.545 0.31 0.19
7 
0.33 0.21
6 
0.1
71 
  
B 0.359 0.2
44 
0.1
77 
3.04 0.628 0.345 1.525 0.287 0.17
7 
3.247 0.96
4 
0.5
32 
  
C 0.3
83 
0.2
28 
0.1
67 
3.03 0.641 0.35 1.507 0.286 0.17
8 
3.099 0.66
8 
0.3
72 
  
D 0.4
24 
0.2
66 
0.1
92 
3.247 0.82 0.428 3.187 0.877 0.44
1 
2.12 0.26
8 
0.4
25 
  
E 0.425 0.2
7 
0.1
86 
3.239 0.811 0.433 3.16 0.837 0.44
5 
1.224 0.16
6 
0.2
62 
  
F 0.418 0.2
68 
0.1
79 
3.18 0.79 0.41 3.272 0.83 0.43
4 
0.681 0.06
1 
0.1
66 
  
G 0.346 0.2
25 
0.1
57 
3.247 0.965 0.494 3.066 0.64 0.34
3 
0.402 2.15
8 
0.1
2 
  
H 0.343 0.2
16 
0.1
55 
3.289 0.984 0.535 3.122 0.659 0.34
1 
0.249 1.27 0.0
63 
  
               
BSA (mg/mL)     0 0.031
25 
0.062
5 
0.125 0.25 0.5 1 2    
Stds Rep 1   0.061 0.166 0.268 0.249 0.402 0.68
1 
1.224 2.12    
Stds Rep 2   0.063 0.12 0.166 0.262 0.425  1.27 2.15
8 
   
Stds Rep 3               
Stds Rep 4               
Averag
e 
   0.062 0.143 0.217 0.255
5 
0.413
5 
0.68
1 
1.247 2.13
9 
   
SD       0.001
414 
0.032
527 
0.072
125 
0.009
192 
0.016
263 
#DIV
/0! 
0.032
527 
0.02
687 
   
               
               
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
y = -0.1211x2 + 1.2624x + 
0.0992 
R² = 0.999 
y = 1.0285x + 0.1345 
R² = 0.9951 
0 
0.5 
1 
1.5 
2 
2.5 
0 1 2 3 A
b
s
o
rb
a
n
c
e
 a
t 
5
4
0
n
m
 
BSA ug/mL 
Average BSA 
Average 
0 
0.5 
1 
1.5 
2 
2.5 
0.01 0.1 1 10 
A
b
s
o
rb
a
n
c
e
 a
t 
5
4
0
n
m
 
BSA ug/mL 
Average BSA 
A… 
Protein Standard plot 
Final protein concentration calculations 
Raw Data Microsomes LM HM 
0.02 0.01 0.005 1 0.1 0.04 1 0.1 0.04 
Dog 0.389 0.269 0.198 3.011 0.685 0.377 1.545 0.31 0.197 
0.359 0.244 0.177 3.04 0.628 0.345 1.525 0.287 0.177 
0.383 0.228 0.167 3.03 0.641 0.35 1.507 0.286 0.178 
Average 0.377 0.247 0.1806667 3.027 0.651333 0.3573333 1.525667 0.294333 0.184 
SEM 0.0091652 0.0119304 0.0091348 0.008505 0.017247 0.0099387 0.010975 0.007839 0.006506 
            
HRN 
Mouse 
0.424 0.266 0.192 3.247 0.82 0.428 3.187 0.877 0.441 
0.425 0.27 0.186 3.239 0.811 0.433 3.16 0.837 0.445 
0.418 0.268 0.179 3.18 0.79 0.41 3.272 0.83 0.434 
Average 0.4223333 0.268 0.1856667 3.222 0.807 0.4236667 3.206333 0.848 0.44 
SEM 0.0021858 0.0011547 0.0037565 0.021127 0.008888 0.0069841 0.033746 0.01464 0.003215 
            
Mouse 0.346 0.225 0.157 3.247 0.965 0.494 3.066 0.64 0.343 
0.343 0.216 0.155 3.289 0.984 0.535 3.122 0.659 0.341 
0.33 0.216 0.171 3.247 0.964 0.532 3.099 0.668 0.372 
Average 0.3396667 0.219 0.161 3.261 0.971 0.5203333 3.095667 0.655667 0.352 
SEM 0.0049103 0.003 0.0050332 0.014 0.006506 0.0131951 0.016251 0.008253 0.010017 
          
          
          
Protein 
(mg/mL) 
Microsomes LM HM 
0.02 0.01 0.005 1 0.1 0.04 1 0.1 0.04 
Dog 0.23 0.14 0.08 3.45 0.49 0.22 1.31 0.17 0.08 
0.21 0.12 0.06 3.51 0.44 0.20 1.29 0.15 0.06 
0.23 0.10 0.05 3.49 0.45 0.20 1.27 0.15 0.06 
Average 0.22 0.12 0.06 3.48 0.46 0.21 1.29 0.16 0.07 
SEM 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 
            
HRN 
Mouse 
0.26 0.13 0.07 4.13 0.61 0.27 3.92 0.66 0.28 
0.26 0.14 0.07 4.10 0.60 0.27 3.84 0.62 0.28 
0.26 0.14 0.06 3.90 0.58 0.25 4.23 0.62 0.27 
Average 0.26 0.14 0.07 4.04 0.59 0.26 4.00 0.63 0.28 
SEM 0.00 0.00 0.00 0.07 0.01 0.01 0.12 0.01 0.00 
            
Mouse 0.20 0.10 0.05 4.13 0.74 0.32 3.58 0.45 0.20 
0.20 0.09 0.04 4.30 0.76 0.36 3.73 0.46 0.20 
0.19 0.09 0.06 4.13 0.74 0.35 3.66 0.47 0.22 
Average 0.19 0.10 0.05 4.19 0.74 0.35 3.66 0.46 0.20 
SEM 0.00 0.00 0.00 0.06 0.01 0.01 0.04 0.01 0.01 
 
Conc. 
adjusted 
protein 
(mg/mL) 
 
Microsomes 
 
LM 
 
HM 
0.02 0.01 0.005 1 0.1 0.04 1 0.1 0.04 
Dog 11.74 13.63 15.77 3.45 4.87 5.62 1.31 1.70 1.95 
10.50 11.60 12.40 3.51 4.37 4.96 1.29 1.51 1.55 
11.49 10.30 10.80 3.49 4.48 5.07 1.27 1.50 1.57 
Average 11.25 11.84 12.99 3.48 4.57 5.22 1.29 1.57 1.69 
SEM 0.38 0.97 1.47 0.02 0.15 0.21 0.01 0.06 0.13 
   12.03   4.90   1.63   
HRN 
Mouse 
13.20 13.38 14.81 4.13 6.06 6.68 3.92 6.58 6.95 
13.24 13.71 13.84 4.10 5.98 6.79 3.84 6.21 7.04 
12.95 13.55 12.72 3.90 5.79 6.31 4.23 6.15 6.81 
Average 13.13 13.55 13.79 4.04 5.95 6.59 4.00 6.31 6.93 
SEM 0.09 0.09 0.60 0.07 0.08 0.15 0.12 0.13 0.07 
   13.49   6.27   6.62   
Mouse 9.97 10.06 9.20 4.13 7.38 8.07 3.58 4.48 4.92 
9.84 9.34 8.88 4.30 7.56 8.94 3.73 4.64 4.88 
9.31 9.34 11.44 4.13 7.37 8.87 3.66 4.72 5.52 
Average 9.71 9.58 9.84 4.19 7.44 8.63 3.66 4.61 5.11 
SEM 0.20 0.24 0.81 0.06 0.06 0.28 0.04 0.07 0.21 
  9.71   8.03   4.86  
N.B. Absorbance values at the top end of the samples (so all values 
for neat LM and neat HM), were outside the range of the protein 
standards, and appear to have been well outside the predictive 
range of the assay. 
Disregard neat LM and HM values    
      
 
 
 
 
 
 
 APPENDIX 3 
SDH ASSAY 
 LIGHT MITOCHONDRIAL PELLETS    HEAVY MITOCHONDRIAL PELLETS  
Strain HRN         Strain HRN       
code          code         
dilution 1 1 1 1  dilution 1 1 1 1 
dilution 
factor 
0.005 0.005 0.005 0.00
5 
 dilution 
factor 
0.005 0.005 0.005 0.005 
rate (s
-1
) 0.0004 0.0004 0 0  rate (s
-1
) 0.0008 0.0006 0.0006 0.0006 
Prot conc 
(mg/ml) 
6.27 6.27 6.27 6.27  Prot conc 
(mg/ml) 
6.62 6.62 6.62 6.62 
SDH 
(nmol/min/
mg 
protein) 
38.86480
6 
38.86480
6 
0 0   SDH 
(nmol/min/
mg 
protein) 
73.56769
9 
55.17577
5 
55.17577
5 
55.17577
5 
MEAN 38.86        MEAN 59.77375
6 
      
SD 0        SD 9.195962
4 
      
           
           
Strain Wild-
type 
       Strain Wild-
type 
      
code          code         
dilution 1 1 1 1  dilution 1 1 1 1 
dilution 
factor 
0.005 0.005 0.005 0.00
5 
 dilution 
factor 
0.005 0.005 0.005 0.005 
rate (s
-1
) 0.0004 0.0004      rate (s
-1
) 0.0002 0.0003 0.0004 0.0003 
Prot conc 
(mg/ml) 
8.03 8.03 8.03 8.03  Prot conc 
(mg/ml) 
4.86 4.86 4.86 4.86 
SDH 
(nmol/min/
mg 
protein) 
30.33833
3 
30.33833
3 
0 0   SDH 
(nmol/min/
mg 
protein) 
25.07021
5 
37.60532
3 
50.14043
1 
37.60532
3 
MEAN 30.34        MEAN 37.61       
SD 0        SD 10.23487
3 
      
           
           
                      
Strain Dog        Strain Dog       
code          code         
dilution 1 1 1 1  dilution 1 1 1 1 
dilution 
factor 
0.005 0.005 0.005 0.00
5 
 dilution 
factor 
0.005 0.005 0.005 0.005 
rate (s
-1
) 0.0002 0.0002 0.0002    rate (s
-1
) 0.0001 0.0001 0.0001 0.0001 
Prot conc 
(mg/ml) 
4.90 4.90 4.90 4.90  Prot conc 
(mg/ml) 
1.63 1.63 1.63 1.63 
SDH 
(nmol/min/
mg 
protein) 
24.88409
6 
24.88409
6 
24.88409
6 
0   SDH 
(nmol/min/
mg 
protein) 
37.37178
1 
37.37178
1 
37.37178
1 
37.37178
1 
MEAN 24.88        MEAN 37.37       
 
 
APPENDIX 4 
Cytochrome c reductase assay 
code dilution dilution 
factor 
rate Prot conc 
(mg/ml) 
 CYTC Reductase 
(nmol/min/mg protein) 
dog 5b 
270412 
5 0.009091 0.0022 12.03 57.20296 
dog 10a 
270412 
10 0.004545 0.001 12.03 52.00269 
DLMA 10 0.004545 0.0009 12.03 46.80243 
DLMB 10 0.004545 0.001 12.03 52.00269 
dog 5a 
260412 
5 0.009091 0.0016 12.03 41.60216 
dog 
5b.260412 
5 0.009091 0.0014 12.03 36.40189 
dog 10a2 
260412 
10 0.004545 0.0006 12.03 31.20162 
dog 10b2. 
260412 
10 0.004545 0.0005 12.03 26.00135 
      
            
      
code dilution dilution 
factor 
rate 
(s-1) 
Prot conc 
(mg/ml) 
 CYTC Reductase 
(nmol/min/mg protein) 
hrn mouse 
10a 
10 0.004545 0.00007 13.49 3.246217 
hrn mouse 
10b 
10 0.004545 0.0001 13.49 4.637453 
hrn mouse 
20 a 
20 0.002273 0.0001 13.49 9.274906 
hrn mouse 
20b 
20 0.002273 0.00009 13.49 8.347415 
hrn_a1 10 0.004545 0.0002 13.49 9.274906 
hrn_a2 10 0.004545 0.0002 13.49 9.274906 
hrn_a3 10 0.004545 0.0002 13.49 9.274906 
      
      
      
wt_1a 10 0.004545 0.0013 9.71 83.75594 
wt_1b 10 0.004545 0.0014 9.71 90.1987 
wt_1c 10 0.004545 0.0014 9.71 90.1987 
MLMA 10 0.004545 0.0015 9.71 96.64147 
MLMB 10 0.004545 0.0016 9.71 103.0842 
MLMC 10 0.004545 0.0012 9.71 77.31317 
mouse 
10a.26.04 
10 0.004545 0.0014 9.71 90.1987 
mouse 10b 10 0.004545 0.0015 9.71 96.64147 
 
 
 
 
 
  
APPENDIX 5
GENERIC INCUBATION PLAN FOR CVB ASSAY
Biological 
sample HRN WT Dog HRN WT Dog WT Dog HRN WT Dog HRN WT Dog
final 
conc
Pre-Incubate Microsomes 37.1 51.5 41.6 37.1 51.5 41.6 51.5 41.6 37.1 51.5 41.6 18.6 25.8 20.8 1mg/ml
NADPH (20mM 
stock) 50.0 50.0 50.0 x x x 50 50 x x x 25.0 25.0 25.0 2mM
UDPGA (50mM 
stock) x x x x x x x x 40.0 40.0 40.0 x x x 4mM
ABT (50 mM 
stock) x x x x x x 10 10 x x x x x x 1mM
Buffer x x x 50.0 50.0 50.0 x x x x x x x x
Add to start 
preincubatio
n
Buffer    
(pre-
warmed)
410.1 395.7 405.6 410.1 395.7 405.6 385.7 395.6 420.1 405.7 415.6 206.4 199.3 204.2
Add at time 
0
1.8 mM 
stock 
solution 
(µL)
2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8 x x x 10µM
TOTAL VOLUME 500 500 500 500 500 500 500 500 500 500 500 250 250 250
Add at T=60
1.8 mM 
stock 
solution 
(µL)
x x x x x x x x x x x 1.4 1.4 1.4 10µM
HRN mcsm WT mcsm Dog mcsm NADPH Buffer ABT UDPGA Test cmpd microsome prt conc mg/ml
259.7 463.5 374.4 650 10410.7 40 240.0 70 Dog 12.03
2 aliquots 2 aliquots 2 aliquots HRN 13.49
WT 9.71
for 50mM ABT stock, weigh 1mg of ABT and dissolve in 150µl of buffer
for 50mM UDPGA stock, weigh 6.46mg of UDPGA and dissolve in 200µl of buffer
for 20mM NADPH stock, prepare a 16.67mg/ml solution
KEYS
HRN=HRN mouse microsome
WT= wild-type mouse microsome
buffer= 0.1 M Potassium phosphate buffer+ 10mM MgCl2
TOTAL VOLUME REQUIRED (µl)
Description
Incubation Plate
Cmpd to be back-added at 1hr 
(250µl volume)Test Cpd             + NADPH Test Cpd                - NADPH
test 
compound+NADPH+ABT Test Compound+UDPGA
APPENDIX 6
GENERIC PLATE LAYOUT FOR CVB 
Figure 1
Plate layout for microsomal incubation
Plate 1
1 2 3 4 5 6 7 8 9 10 11 12
A HRN+N (a) HRN+N (b) WT+N+ABT(a) WT+N+ABT(b) HRN +N (a) HRN +N (b) 11.2 0
B WT +N (a) WT +N (b) Dog +N + ABT + (a) Dog +N + ABT + (b) WT + N (a) WT + N (b) 11.2 0
C Dog+N (a) Dog+N (b) HRN + UDPGA (a) HRN + UDPGA (b) Dog + N (a) Dog + N (b) 11.2 0
D HRN ‐N (a) HRN ‐N (b) WT + UDPGA (a) WT + UDPGA (b) 11.2
E WT ‐N (a) WT ‐N (a) Dog + UDPGA (a) Dog + UDPGA (b) 11.2
F Dog‐N (a) Dog‐N (b) 5.6
G
H
Plate layout for acetone quench
Plate 2
60 minutes
1 2 3 4 5 6 7 8 9 10 11 12
A HRN+N (a) HRN+N (b) WT+N+ABT(a) WT+N+ABT(b) HRN+N (a) HRN+N (b) WT+N+ABT(a) WT+N+ABT(b) HRN +N (a) HRN +N (b) 1
B WT +N (a) WT +N (b) Dog +N + ABT + (a) Dog +N + ABT + (b) WT +N (a) WT +N (b) Dog +N + ABT + (a) Dog +N + ABT + (b) WT + N (a) WT + N (b) 1
C Dog+N (a) Dog+N (b) HRN + UDPGA (a) HRN + UDPGA (b) Dog+N (a) Dog+N (b) HRN + UDPGA (a) HRN + UDPGA (b) Dog + N (a) Dog + N (b) 1
D HRN ‐N (a) HRN ‐N (b) WT + UDPGA (a) WT + UDPGA (b) HRN ‐N (a) HRN ‐N (b) WT + UDPGA (a) WT + UDPGA (b)
E WT ‐N (a) WT ‐N (a) Dog + UDPGA (a) Dog + UDPGA (b) WT ‐N (a) WT ‐N (a) Dog + UDPGA (a) Dog + UDPGA (b)
F Dog‐N (a) Dog‐N (b) Dog‐N (a) Dog‐N (b)
G
H
Plate layout for acetonitrile + formic acid (metabolite identification)
1 2 3 4 5 6 7 8 9 10 11 12
A HRN+N (a) HRN+N (b) WT+N+ABT(a) WT+N+ABT(b)
B WT +N (a) WT +N (b) Dog +N + ABT + (a) Dog +N + ABT + (b)
Dog+N (a) Dog+N (b) HRN + UDPGA (a) HRN + UDPGA (b)
C WT + UDPGA (a) WT + UDPGA (b)
D Dog + UDPGA (a) Dog + UDPGA (b)
E
F
G
H
 60 minutes
Back‐add
vol of isotope (µl)
vol of isotope (µl)
Cpd Inc
0 minutes Back‐add (60 minutes)
APPENDIX 7 
 
Generic Radioactivity count for 14C-diclofenac  
 
 
 
Cycle 1 Results 
  S#  Count Time    CPMA    DPM1      SIS     tSIE  MESSAGES 
   1       10.00       9      10    68.16   865.96           
   2       10.00      34      36    66.28   786.81           
   3       10.00      34      37    70.93   782.78           
   4       10.00     111     118    68.58   779.13           
   5       10.00      87      92    65.98   793.74           
   6       10.00      18      19    74.00   783.58           
   7       10.00      22      24    64.85   790.06           
   8       10.00      29      31    62.45   789.76           
   9       10.00      38      41    64.40   782.57           
  10       10.00     648     689    70.31   794.63           
  11       10.00     644     685    68.78   785.82           
  12       10.00     245     261    69.68   783.30           
  13       10.00     140     148    68.24   801.54           
  14       10.00      19      20    75.01   783.90           
  15       10.00     205     218    70.69   778.51           
  16       10.00      40      43    65.16   778.94           
  17       10.00      65      69    64.34   780.48           
  18       10.00      93      99    69.21   777.49           
  19       10.00      78      83    66.61   782.99           
  20       10.00      85      90    64.41   779.42           
  21       10.00      99     105    68.20   791.35           
  22       10.00     242     258    68.26   773.74           
  23       10.00     149     159    68.36   780.45           
  24       10.00      50      53    73.84   791.42           
  25       10.00      70      75    71.35   773.11           
  26       10.00     105     112    64.79   778.93           
  27       10.00     103     109    69.47   774.45           
  28       10.00      80      85    67.59   783.05           
  29       10.00      53      57    66.31   772.49           
  30       10.00      56      60    67.93   775.61           
  31       10.00      72      77    66.10   779.24           
  32       10.00     255     272    71.45   780.77           
  33       10.00     185     197    71.67   786.25           
  34       10.00      10      10    85.44   778.87           
  35       10.00       9      10    65.92   788.67           
  36       10.00      12      12    71.51   793.53           
  37       10.00       9      10    80.19   779.61           
 
 
cvb fa2
  
APPENDIX 8 
Generic Radioactivity count for 14C-Feclozic acid
S#  Count Time    CPMA    DPM1      SIS     tSIE  MESSAGES 
   1       10.00       7       7    41.02   880.88          
   2       10.00       9       9    66.66   801.86          
   3       10.00      10      10    61.46   785.76          
   4       10.00       7       7    63.21   794.09          
   5       10.00       9       9    72.63   775.86          
   6       10.00      65      69    70.06   786.90          
   7       10.00      66      71    68.61   778.74          
   8       10.00      98     104    73.32   769.26          
   9       10.00      84      90    66.59   779.66          
  10       10.00      84      89    70.33   786.12          
  11       10.00      88      94    72.10   786.21          
  12       10.00     189     201    70.87   791.79          
  13       10.00     309     329    71.98   783.59          
  14       10.00      80      85    70.15   769.79          
  15       10.00      77      82    71.23   773.74          
  16       10.00      80      85    71.25   770.56          
  17       10.00     150     160    74.75   772.11          
  18       10.00     166     177    71.30   767.84          
  19       10.00     185     197    70.96   779.18          
  20       10.00      84      89    70.26   773.71          
  21       10.00      75      79    74.06   777.35          
  22       10.00     147     156    73.21   770.30          
  23       10.00     100     106    67.77   774.75          
  24       10.00     233     249    71.32   770.57          
  25       10.00     170     180    61.84   838.82          
  26       10.00    1807    1925    72.27   767.87          
  27       10.00    2141    2281    72.64   772.17          
  28       10.00      96     102    72.22   788.14          
  29       10.00     110     117    70.43   766.05          
  30       10.00     485     516    72.04   773.55          
  31       10.00     417     444    73.00   774.01          
  32       10.00      68      72    71.38   766.29          
  33       10.00      58      61    72.69   768.94          
  34       10.00      82      87    73.15   779.72          
  35       10.00      93      99    74.48   777.35          
  36       10.00     307     327    74.76   773.46          
  37       10.00     393     419    74.14   765.07          
  38       10.00     124     132    71.68   767.66          
  39       10.00     136     145    71.44   765.04          
  40       10.00     145     155    74.84   756.31          
  41       10.00     126     135    74.78   768.01          
  42       10.00     155     165    73.22   770.35          
  43       10.00     131     140    73.35   764.47          
  44       10.00     431     460    72.58   764.04          
  45       10.00     510     543    72.98   758.02          
  46       10.00      92      98    71.29   771.36          
  47       10.00     104     110    70.46   761.22          
  48       10.00     338     360    73.57   764.90          
  49       10.00     321     342    74.99   770.78          
  50       10.00      78      83    72.50   777.82          
  51       10.00      89      95    70.37   762.92          
  52       10.00     120     128    71.63   767.02          
  53       10.00     206     219    73.30   759.74          
  54       10.00     162     173    72.62   760.42          
  55       10.00     149     157    54.32   885.36          
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APPENDIX 9
GENERIC COVALENT BINDING CALCULATIONS
group
r
adioactivity(DPM)
c
o
r
r
e
c
t
ed radioactivity
m
ole equivalent in sample
p
m
ole equivalent
p
r
o
t
ein concentration (µ
g
m
g
 
p
r
o
t
ein in 0.95ml
C
V
B(pmole equiv/mg prote
BL1 7
BL2 (background) 11
BL3 (background) 13
BL4 (background) 11
BL5 (background) 8
Average 10.75
HRN +NADPH, T=0 52 41.25 3.38E-13 3.38E-01 81 0.08 4.41
35 24.25 1.99E-13 1.99E-01 111 0.11 1.88
HRN +NADPH, T=60 98 87.25 7.15E-13 7.15E-01 105 0.10 7.17
82 71.25 5.84E-13 5.84E-01 104 0.10 5.91
HRN -NADPH, T=0 60 49.25 4.03E-13 4.03E-01 143 0.14 2.96
83 72.25 5.92E-13 5.92E-01 112 0.11 5.54
HRN -NADPH, T=60 110 99.25 8.13E-13 8.13E-01 130 0.12 6.57
94 83.25 6.82E-13 6.82E-01 102 0.10 7.02
HRN + UDGPA, T=0 77 66.25 5.43E-13 5.43E-01 173 0.16 3.30
80 69.25 5.67E-13 5.67E-01 189 0.18 3.15
HRN + UDGPA, T=60 122 111.25 9.11E-13 9.11E-01 132 0.13 7.28
170 159.25 1.30E-12 1.30E+00 212 0.20 6.49
HRN BA 35 24.25 1.99E-13 1.99E-01 109 0.10 1.92
51 40.25 3.30E-13 3.30E-01 158 0.15 2.20
WT + NADPH, T=0 48 37.25 3.05E-13 3.05E-01 119 0.11 2.70
37 26.25 2.15E-13 2.15E-01 117 0.11 1.94
WT + NADPH, T=60 456 445.25 3.65E-12 3.65E+00 132 0.13 29.12
434 423.25 3.47E-12 3.47E+00 125 0.12 29.18
WT + ABT, T=0 39 28.25 2.31E-13 2.31E-01 129 0.12 1.88
27 16.25 1.33E-13 1.33E-01 152 0.14 0.92
WT + ABT, T=60 114 103.25 8.46E-13 0.8456175 122 0.12 7.32
135 124.25 1.02E-12 1.0176075 141 0.13 7.60
WT -NADPH, T=0 88 77.25 6.33E-13 0.6326775 125 0.12 5.35
74 63.25 5.18E-13 0.5180175 110 0.10 4.94
WT -NADPH, T=60 118 107.25 8.78E-13 0.8783775 89 0.08 10.38
71 60.25 4.93E-13 0.4934475 38 0.04 13.81
WT + UDPGA, T=0 66 55.25 4.52E-13 0.4524975 136 0.13 3.49
51 40.25 3.30E-13 0.3296475 146 0.14 2.38
WT + UDPGA, T=60 125 114.25 9.36E-13 0.9357075 85 0.08 11.60
194 183.25 1.50E-12 1.5008175 133 0.13 11.89
WT BA 79 68.25 5.59E-13 0.5589675 113 0.11 5.20
21 10.25 8.39E-14 0.0839475 73 0.07 1.21
DOG + NADPH, T=0 77 66.25 5.43E-13 0.5425875 84 0.08 6.83
58 47.25 3.87E-13 0.3869775 96 0.09 4.26
DOG + NADPH, T=60 479 468.25 3.83E-12 3.8349675 66 0.06 61.25
648 637.25 5.22E-12 5.2190775 96 0.09 57.41
DOG + ABT, T=0 31 20.25 1.66E-13 0.1658475 89 0.08 1.96
34 23 1.88E-13 0.18837 112 0.11 1.76
DOG + ABT, T=60 191 180 1.47E-12 1.4742 76 0.07 20.31
399 388 3.18E-12 3.17772 110 0.10 30.48
DOG -NADPH, T=0 95 84 6.88E-13 0.68796 72 0.07 9.99
52 41 3.36E-13 0.33579 63 0.06 5.64
DOG -NADPH, T=60 87 76 6.22E-13 0.62244 64 0.06 10.22
69 58 4.75E-13 0.47502 53 0.05 9.44
DOG + UDPGA, T=0 45 34 2.78E-13 0.27846 64 0.06 4.59
40 29 2.38E-13 0.23751 60 0.06 4.16
DOG + UDPGA, T=60 233 222 1.82E-12 1.81818 52 0.05 36.79
288 277 2.27E-12 2.26863 64 0.06 37.54
DOG BA 194 183 1.50E-12 1.49877 178 0.17 8.85
71 60 4.91E-13 0.4914 139 0.13 3.71
BLANK 7
Background 13
12
9
10 11
molar radioactivity of (C-14) 
diclofenac mole /dpm  
8.19E-15
APPENDIX 10
FENCLOZIC ACID COVALENT BINDING
Fenclozic acid Covalent binding assay data
HRN -NADPH, T=0 HRN -NADPH, T=60 HRN +NADPH, T=0 HRN +NADPH, T=60 HRN + ABT, T=0 HRN + ABT, T=60 HRN + UDGPA, T=0 HRN + UDGPA, T=60 HRN BA
4.94 7.02 7.21 23.79 10.92 7.03 21.75
5.88 8.70 4.52 23.62 5.52 5.64 15.74
5.78 10.07 9.93 40.77 9.55 7.69 16.55
5.76 10.46 8.80 33.93 7.99 10.38 21.23
7.34 11.72 12.73 36.40 10.430 26.222 7.23 11.56 12.02
6.03 10.91 10.91 34.36 10.456 32.089 7.67 12.63 10.59
mean 5.96 9.81 9.02 32.15 10.44 29.16 8.15 9.15 16.31
Exp 1
Exp 2
Exp 3
SD 0.78 1.70 2.89 6.97 0.02 4.15 1.88 2.77 4.59
WT -NADPH, T=0 WT -NADPH, T=60 WT + NADPH, T=0 WT + NADPH, T=60 WT + ABT, T=0 WT + ABT, T=60 WT + UDPGA, T=0 WT + UDPGA, T=60 WT BA
4.01 10.87 13.34 134.60 8.31 31.93 7.75 10.36 35.58
6.70 7.53 23.93 172.17 7.72 22.77 10.38 15.00 32.63
8.22 12.36 25.59 204.03 12.56 46.97 6.16 9.18 35.39
7.97 7.70 16.64 208.91 10.57 44.47 4.64 9.74 46.40
8.631 10.273 18.282 189.879 9.438 47.887 6.715 8.739 22.000
10.870 9.272 18.535 216.787 9.327 43.198 6.986 9.434 26.167
mean 7.73 9.67 19.39 187.73 9.65 39.54 7.10 10.41 33.03
SD 2 28 1 88 4 59 30 42 1 73 10 02 1 91 2 31 8 48
Exp 1
Exp 2
Exp 3
. . . . . . . . .
DOG -NADPH, T=0 DOG -NADPH, T=60 DOG + NADPH, T=0 DOG + NADPH, T=60 DOG + ABT, T=0 DOG + ABT, T=60 DOG + UDPGA, T=0 DOG + UDPGA, T=60 DOG BA
7.89 9.23 14.95 83.17 9.37 36.54 7.79 12.24 19.22
0.00 0.00 15.34 56.12 4.51 33.00 6.75 8.49 16.36
16.12 21.17 23.63 87.92 13.94 44.81 9.24 18.07 12.91
8.924 10.750 17.149 72.149 12.723 26.135 8.535 13.027 10.551
8.726 11.391 18.402 38.467 19.031 21.593 7.878 10.325 12.881
14.86 16.51 21.38 64.71 9.40 44.87 10.79 28.07 14.50
mean 9.42 11.51 18.47 67.09 11.50 34.49 8.50 15.04 14.40
SD 5.77 7.16 3.43 18.24 4.94 9.56 1.39 7.16 3.05
Exp 1
Exp 2
Exp 3
APPENDIX  11
COVALENT BING ASSAY IN [14C]-DICLOFENAC
HRN -NADPH, T=0 HRN -NADPH, T=60 HRN +NADPH, T=0 HRN +NADPH, T=60 HRN + ABT T=0 HRN + ABT T=60HRN + UDGPA, T=0 HRN + UDGPA, T=6 HRN BA
3.29 9.87 2.40 9.14 6.10 21.28 0.78
5.69 7.32 3.16 8.18 5.21 12.43 0.96
2.96 6.57 4.41 7.17 3.30 7.28 1.92
5.54 7.02 1.88 5.91 3.15 6.49 2.20
10.137 14.512 11.980 18.448 10.418 16.731 11.636 22.571 13.983
11.738 16.057 9.983 17.132 9.569 16.290 12.486 25.750 13.268
6 6 10 22 6 11 00 9 99 16 1 6 98 1 9 2
EXP 1 1005
EXP2 1405
EXP4 608
means .5 . 5. 4 . . .5 . 5. 7 5.5
SD 3.61 4.11 4.27 5.39 0.60 0.31 4.10 8.31 6.31
geomean 5.76 9.59 4.43 10.00 9.98 16.51 6.03 13.91 2.89
SEM 1.47 1.68 1.74 2.20 0.42 0.22 1.67 3.39 2.58
WT NADPH T 0 WT NADPH T 60 WT NADPH T 0 WT NADPH T 60 WT ABT T 0 WT ABT T 60WT UDPGA T 0 WT UDPGA T 60 WT BA - , =  - , =  + , =  + , =  + , =  + , =  + , =  + , =  
2.81 7.91 1.35 48.37 5.41 20.49 3.86 17.71 0.80
5.56 6.30 2.46 50.61 3.17 8.29 4.75 11.71 17.01
5.35 10.38 2.70 29.12 1.88 7.32 3.49 11.60 5.20
4.94 13.81 1.94 29.18 0.92 7.60 2.38 11.89 1.21
10.993 17.998 7.891 32.058 7.934 13.051 11.874 25.151 12.201
13.728 16.678 6.938 32.526 5.365 16.919 11.374 26.087 15.145
means 7.23 12.18 3.88 36.98 4.11 12.28 6.29 17.36 8.59
EXP2 1005
EXP3 1405
EXP5 608
SD 4.18 4.75 2.79 9.82 2.60 5.51 4.20 6.81 7.12
geomean 6.29 11.36 3.14 35.98 3.29 11.31 5.24 16.30 5.01
SEM 1.71 1.94 1.14 4.01 1.06 2.25 1.72 2.78 2.91
DOG -NADPH, T=0 DOG -NADPH, T=60 DOG + NADPH, T=0DOG + NADPH, T=6 DOG + ABT, T=0DOG + ABT, T=6DOG + UDPGA, T=0 DOG + UDPGA, T=6 DOG BA
9.99 10.22 6.83 61.25 1.96 20.31 4.59 36.79 8.85
5.64 9.44 4.26 57.41 1.76 30.48 4.16 37.54 3.71
8.59 12.70 5.35 85.92 3.91 46.49 10.09 46.52 11.27
5.59 10.70 7.38 73.10 10.21 56.26 7.18
11.876 19.250 11.679 60.929 10.354 19.062 8.491 53.632 6.773
7.653 19.890 14.689 48.026 8.334 13.370 6.557 61.505 6.793
means 8.22 13.70 8.36 64.44 5.26 25.94 7.35 48.71 7.43
SD 2.47 4.68 4.01 13.25 3.88 13.04 2.66 10.16 2.51
EXP2 1405
EXP3 2505
EXP4 608
geomean 7.91 13.09 7.63 63.35 4.11 23.61 6.92 47.80 7.05
SEM 1.01 1.91 1.64 5.41 1.74 5.83 1.09 4.15 1.02
APPENDIX 12
BODY WEIGHT OF WILD-TYPE AND HRN MICE
C57BL6J Control C57BL6J Diclofenac 10 mg/kg
day -2 day-1 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 day-2 day-1 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8
1 23.6 23.8 23.1 22.9 23.7 23.1 23.4 23.6 23.7 24.4 6 20.8 21.3 21.3 21.3 21.5 21.5 21.7 21.5 21.9 22.5
2 22.7 23.5 23.1 22.1 22.2 21.8 22.4 22.9 22.5 22.8 7 23.8 24 23.8 24 23.9 24.1 24.8 25.1 24.9 25.4
3 22 22.4 22.4 22.2 22.7 22 21.9 21.8 22.1 22.2 8 24.7 24.7 24.3 24 24.3 24.8 24.6 24.8 24.9 25.4
4 25.1 25.5 24.6 23.8 24.4 24.5 24.3 24.5 25.1 25.9 9 24.1 24.7 25 24.6 25 25.1 24.8 25.2 25 25.6
5 21.9 21.7 20.9 21.2 21.6 21.7 21.6 22.2 22.6 23.1 10 21.6 21.8 21.9 21.4 21.6 22 21.7 21.8 21.8 22
mean 23.06 23.38 22.82 22.44 22.92 22.62 22.72 23 23.2 23.68 mean 23 23.3 23.26 23.06 23.26 23.5 23.52 23.68 23.7 24.18
SD 1.3278 1.4550 1.3405 0.9711 1.1300 1.1904 1.1167 1.0840 1.2166 1.4789 SD 1.6985 1.6325 1.5884 1.5805 1.6103 1.6477 1.6634 1.8620 1.6897 1.7726
C57BL6J Diclofenac 20mg/kg C57BL6J diclofenac 30mg/kg
day-2 day-1 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 Day-2 Day-1 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8
11 23.7 24.2 23.6 23.4 23.8 23.7 23.8 23.7 24.1 24.2 16 22.7 23.2 22.7 22.9 23 22.8 23.1 23.4 23.5 23.6
12 21.6 21.8 21.2 20.8 21.4 21.5 21.5 21.2 21.4 22 17 21.5 21.6 21.7 21.4 21.3 21.2 21.7 21.8 20.6 20
13 24.1 24.6 24.1 23.9 24.3 24.2 24.6 24.7 24.8 24.4 18 23.5 23.7 23.2 23.1 23.1 23.1 23.5 24 23.4 23.1
14 23.7 24 23.7 24 24.3 24.4 24.4 24.3 23.7 24.6 19 24.6 24.7 25 24.7 25.4 25.1 25.5 25.7 25.5 26.2
15 23.2 23.5 23.2 22.8 23.1 23.1 23 22.8 23.1 23.2 20 25.1 25 24.6 24.5 24.2 24.1 24.2 24.8 24.1 24.5
mean 23.26 23.62 23.16 22.98 23.38 23.38 23.46 23.34 23.42 23.68 mean 23.48 23.64 23.44 23.32 23.4 23.26 23.6 23.94 23.42 23.48
SD 0.9813 1.0918 1.1415 1.3084 1.2112 1.1649 1.2602 1.3939 1.2872 1.0826 SD 1.4498 1.3539 1.3612 1.3424 1.5248 1.4639 1.4000 1.4758 1.7852 2.2753
C57BL6J Fenclozic acid 50mg/kg C57BL6J Fenclozic acid 100mg/kg
day-2 day-1 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 day-2 day-1 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8
21 21 8 22 22 2 21 9 22 2 21 7 22 2 22 3 22 7 23 3 26 23 1 23 3 23 22 4 22 5 22 3 23 1 23 5 23 2 23 4. . . . . . . . . . . . . . . . . .
22 23.5 24 23.7 23.2 23.4 23.3 23.5 23.6 23.5 24 27 22.6 22.9 22.6 21.7 22 22 21.9 22.6 21.9 22.3
23 23.9 24.3 24.9 24 24.6 23.8 24.1 24.5 24.4 24.8 28 20.8 21.2 21.5 20.9 21.2 21 21.6 22.4 22.5 21.7
24 23.8 23.7 23.9 22.9 23.8 23 23.4 23.8 23.7 23.9 29 24.9 24.9 25.4 24 24.5 24.7 24.6 24.4 24.2 24.7
25 23.5 23.6 23.3 22.9 23.2 23.4 23.7 23.4 23.3 23.8 30 22.8 23.2 23.4 22.7 23.1 22.8 23.1 23.7 23.4 23.7
mean 23.3 23.52 23.6 22.98 23.44 23.04 23.38 23.52 23.52 23.96 mean 22.84 23.1 23.18 22.34 22.66 22.56 22.86 23.32 23.04 23.16
SD 0.8573 0.8927 0.9798 0.7530 0.8764 0.8019 0.7120 0.7981 0.6181 0.5413 SD 1.4605 1.3172 1.4290 1.1589 1.2422 1.3649 1.1887 0.8228 0.8792 1.1824
HRN control HRN diclofenac 30mg/kg
Day-2 Day-1 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 day-2 day-1 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8
31 23.7 23.8 23.6 23.4 23.8 23.5 23.2 24.1 24.3 23.9 35 19.2 19.3 18.6 18.5 18.8 18.8 18.9 18.9 19 19.1
32 20.6 20.7 20.6 20.2 20.5 20.3 20 20.2 20.9 21.1 36 25.6 25.7 25.8 24.9 26.4 25 25.7 25.1 25.2 25.2
33 19.7 19.7 20 19.3 19.9 20.1 20.1 20.5 20.3 19.9 37 21.1 21.1 21.1 20.9 21.1 20 20 19.4 19 19
34 26.7 26.8 26.2 25.5 25.8 25.2 25.7 25.6 26 25.9 38 25.9 25.6 25.4 25.6 25.7 25.2 24.5 24.2 24.8 25
39 24.4 24.6 24.7 23.8 24.9 23.8 25.6 26.4 25.9 25.2
mean 22.675 22.75 22.6 22.1 22.5 22.275 22.25 22.6 22.875 22.7 mean 23.24 23.26 23.12 22.74 23.38 22.56 22.94 22.8 22.78 22.7
SD 3 1837 3 2151 2 8705 2 8694 2 7893 2 4958 2 7380 2 6721 2 7281 2 7129 SD 2 9535 2 8971 3 1380 2 9720 3 2783 2 9645 3 2439 3 4271 3 4730 3 3332. . . . . . . . . . . . . . . . . . . .
HRN fenclozic acid 100mg/kg
Day-2 Day-1 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8
40 22.5 22.8 23.2 22.5 22.2 22.2 22.4 22.7 23 22.8
41 22.7 22.3 21.8 20.8 20.7 20.4 20.9 20.9 20.8 20.6
42 19.7 19.7 19.4 18.7 19.1 18.8 18.9 19.3 19.3 19.4
43 23.8 23.8 24.4 22.9 22.5 22.3 22.9 22.9 23.9 23.8
44 26.9 26.9 27.1 26.1 26.2 25.9 26.3 26.9 26.4 26.8
mean 23.12 23.1 23.18 22.2 22.14 21.92 22.28 22.54 22.68 22.68
SD 2.5985 2.6086 2.8744 2.7386 2.6425 2.6508 2.7335 2.8439 2.7563 2.8865
APPENDIX 13
FOOD INTAKE IN WILD-TYPE AND HRN MICE
food consumption
C57BL6J Control C57BL6J Diclofenac 10mg/kg
day -2 day -1 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 day -1 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8
M 1 5 3.8 3.7 6.2 1.9 3.6 3.6 4.3 4.3 4.4 M 6 4 4.5 4 4.1 3.5 3.9 3.8 3.4 3.7 5.9
M 2 5 4.6 4.3 3.8 3.3 3.3 3.5 4.8 3.8 3.8 M 7 5 4.8 4.5 4 3.7 4.3 4.5 4.4 4.1 4.3
M 3 4 4.5 4.8 4 4.6 3.7 4.3 3.2 4.2 3.7 M 8 4 5 4.1 3.7 4 4.1 4.2 3.9 4.3 4.2
M 4 4 5.3 3.7 2.9 3.3 4.3 4.3 3.5 4.8 4.7 M 9 4 4.7 5.1 4 4.3 4.4 4.7 3.7 4.5 4.8
M 5 4 4.2 3.1 3.8 3.3 4.3 5.3 1.9 4.1 4.4 M 10 3 4.7 4.5 3.5 3.8 4 4.8 2.6 4 3.8
Mean 4 4 4 48 3 92 4 14 3 28 3 84 4 2 3 54 4 24 4 2 Mean 4 4 74 4 44 3 86 3 86 4 14 4 4 3 6 4 12 4 6. . . . . . . . . . . . . . . . . . .
SD 0.5477 0.5541 0.6496 1.2280 0.9550 0.4450 0.7211 1.1149 0.3647 0.4301 SD 0.7071 0.1817 0.4336 0.2510 0.3050 0.2074 0.4062 0.6671 0.3033 0.8093
food consumption
C57BL6J Diclofenac 20mg/kg C57BL6J Diclofenac 30 mg/kg
day -2 day -1 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 day -2 day -1 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8
M 11 5.3 4.5 4.3 4.3 4.4 4.7 4.1 4.8 4.5 4.7 M 16 4.9 4.3 4.6 4.4 4.5 4.3 4.4 4.2 4.9 4.7
M 12 4.7 4.3 3.5 3.4 4.3 4.5 3.7 3.5 3.7 4.9 M 17 4.4 4.6 4.3 4.6 4 3.7 3.1 3.1 3.1 3.4
M 13 4.5 4.4 4 4 4.5 4.9 4.1 4.1 4.2 4.1 M 18 4.6 4.7 4.2 4.6 4.1 3.8 3.9 4.5 4 4.2
M 14 5 4.8 4.4 4.7 5.5 5.6 4.4 5.2 4.2 5.8 M 19 5.9 7 6.1 4.9 5.8 4.9 5.4 5.2 4.7 5
M 15 3.9 4.7 3.8 4 5 5.8 3.8 3.1 4 3.9 M 20 5.6 4.2 4.8 4.4 4.1 4.4 3.9 4.1 4.4 4.5
Mean 4.68 4.54 4 4.08 4.74 5.1 4.02 4.14 4.12 4.68 Mean 5.08 4.96 4.8 4.58 4.5 4.22 4.14 4.22 4.22 4.36
SD 0.5310 0.2074 0.3674 0.4764 0.5030 0.5701 0.2775 0.8735 0.2950 0.7497 SD 0.6458 1.1589 0.7649 0.2049 0.7517 0.4868 0.8444 0.7596 0.7120 0.6107
food consumption
C57BL6J Fenclozic acid 50mg/kg C57BL6J Fenclozic acid 100mg/kg      
day -2 day -1 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 day -2 day -1 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8
M 21 4 4.3 4.1 3.8 3.6 3.5 3.7 4.1 4 4.5 M 26 5.1 5.3 4.2 4 4 4 4.8 4.4 5 4.6
M 22 4 3.6 4.6 3.6 3.2 3.5 3.5 4.2 3.8 4.1 M 27 5.4 4.8 4.1 3.9 4.8 4.6 4 4.5 3.9 4.4
M 23 4 5 5.5 4.4 4 3.8 3.6 4.7 4.8 4.4 M 28 5.2 4.7 4.2 4.7 4.3 4.6 4.5 4.3 4.8 4.6
M 24 4 4.8 4.6 3.4 3.9 3.8 3.3 4.8 4.1 3.8 M 29 5.9 5.1 5.3 4 4.6 5.4 5.3 4.5 5.2 5.7
M 25 4 4.5 4.3 4.2 3.2 3.8 3.6 4.5 4.2 3.9 M 30 5.1 5 4.1 4.5 4.6 5.4 4.8 5.2 4.2 5.3
Mean 4 4.44 4.62 3.88 3.58 3.68 3.54 4.46 4.18 4.14 Mean 5.34 4.98 4.38 4.22 4.46 4.8 4.68 4.58 4.62 4.92
SD 0.0000 0.5413 0.5357 0.4147 0.3768 0.1643 0.1517 0.3050 0.3768 0.3050 SD 0.3362 0.2387 0.5167 0.3564 0.3130 0.6000 0.4764 0.3564 0.5495 0.5541
HRN Control HRN Diclofenac 30 mg/kg
day -2 day -1 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 day -2 day -1 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8
M 31 5.3 5 4.7 4.8 4.4 4.6 4.2 5.7 4.9 5.3 M 35 4.8 4.8 4 4.2 4.4 4.4 4 5.1 4.6 4.4
M 32 4.5 4.7 4.7 3.7 4.4 4.1 3.8 4.7 4.8 5.2 M 36 5.9 6.1 5.8 5.4 5.7 4.9 4.7 5 5.6 4.8
M 33 4.5 4.5 4.1 4.3 4.9 4.6 4.7 4.9 4.2 5.1 M 37 4.1 4.1 4.1 4.3 3.8 2.2 3.4 8.1 4.7 5.7
M 34 5.6 5.3 4.8 5 4.6 4.6 4.6 5.2 5.2 4.9 M 38 5.5 5.1 5.1 5.3 4.6 3.9 1.5 4.1 5 6.4
M 39 5 4 5 3 5 4 5 1 5 3 3 4 4 3 3 6 5 2 6 5 . . . . . . . . . .
Mean 4.975 4.875 4.575 4.45 4.575 4.475 4.325 5.125 4.775 5.125 Mean 5.14 5.08 4.88 4.86 4.76 3.76 3.58 5.18 5.02 5.56
SD 0.5620 0.3500 0.3202 0.5802 0.2363 0.2500 0.4113 0.4349 0.4193 0.1708 SD 0.7021 0.7294 0.7981 0.5683 0.7503 1.0359 1.2558 1.7484 0.4025 0.9397
HRN Fenclozic acid 100 mg/kg
day -2 day -1 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8
M 40 5.1 5.5 5.5 4.9 4.5 5 5.3 5.3 4.9 4.7
M 41 7.2 5.6 5.3 4.4 4.8 4.8 4.8 5.2 4.4 4.7
M 42 4.8 5 4.8 4 4.5 4.4 3.8 5.1 4.5 4.2
M 43 5.6 5 5.2 3.8 3.6 4.1 4.7 5.3 5.6 5.4
M 44 4.8 4.5 5.4 4.7 4.6 5.3 4.8 6 5.2 6
Mean 5.5 5.12 5.24 4.36 4.4 4.72 4.68 5.38 4.92 5
SD 1.0050 0.4438 0.2702 0.4615 0.4637 0.4764 0.5450 0.3564 0.4970 0.7036
APPENDIX 14
LIVER-TO-BODY WEIGHT RATIO IN 
WILD-TYPE AND HRN MICE
C57BL6J control C57BL6J diclofenac 10mg/kg C57BL6J diclofenac 20mg/kg
SN BW LW LW:BW SN BW LW LW:BW SN BW LW LW:BW
1 24 1.05 0.044 6 22 1.55 0.070 11 23.5 1.58 0.067
2 22.1 1.26 0.057 7 24.7 1.34 0.054 12 21.5 1.45 0.067
3 21.8 1.21 0.056 8 24.6 1.47 0.060 13 23.9 1.61 0.067
4 25 1.63 0.065 9 25.4 1.55 0.061 14 23.8 1.58 0.066
5 22.8 1.33 0.058 10 21.8 1.31 0.060 15 22.2 1.36 0.061
mean 23.14 1.29 0.06 mean 23.70 1.44 0.06 mean 22.98 1.52 0.07
SD 1.341 0.213 0.008 SD 1.673 0.112 0.006 SD 1.071 0.109 0.003
C57BL6J diclofenac 30mg/kg C57BL6J Fenclozic acid 50mg/kg C57BL6J Fenclozic acid 100mg/kg
SN BW LW LW:BW SN BW LW LW:BW SN BW LW LW:BW
16 23 1.52 0.066 21 22.8 1.37 0.060 26 23.1 1.48 0.064
17 19.7 1.03 0.052 22 23.5 1.34 0.057 27 21.7 1.39 0.064
18 22.9 1.47 0.064 23 24.5 1.47 0.060 28 21.5 1.50 0.070
19 25.7 1.74 0.068 24 23.2 1.31 0.056 29 24 1.77 0.074
20 24.1 1.51 0.063 25 23.4 1.41 0.060 30 23 0.00 0.000
mean 23.08 1.45 0.06 mean 23.48 1.38 0.06 mean 22.66 1.23 0.05
SD 2.200 0.256 0.006 SD 0.630 0.062 0.002 SD 1.045 0.701 0.031
HRN control HRN diclofenac 30mg/kg HRN Fenclozic acid 100mg/kg
SN BW LW BW:LW SN BW LW LW:BW SN BW LW LW:BW
31 23.9 2.55 0.107 35 19.2 2.25 0.117 40 22.6 2.59 0.115
32 20.7 2.32 0.112 36 25.2 2.49 0.099 41 20.6 2.34 0.114
33 20.3 2.06 0.101 37 20 2.25 0.113 42 19.1 2.03 0.106
34 25.3 2.84 0.112 38 25.6 2.46 0.096 43 23.9 2.90 0.121
mean 22.55 2.44 0.11 39 24.6 2.79 0.113 44 26.3 2.84 0.108
SD 2.441 0.333 0.005 mean 22.92 2.45 0.11 mean 22.50 2.54 0.11
SD 3.065 0.222 0.010 SD 2.810 0.362 0.006
APPENDIX 15
TIME-DEPENDENT CHANGE IN ALT IN WILD-TYPE AND HRN MICE
Day of treatment CONTROL
Day -1 Day 2 Day 4 Day 8 Day 8 auto DICLOFENAC (10MG/KG)
M 1 20.6 13.3 24.1 31.6 59 Day -1 Day 2 Day 4 Day 8 Day 8 auto
M 2 25.1 24.5 22.2 21.6 32 M 6 21.92 16.45 14.07 15.73 32
M 3 22.2 21.4 25.5 18.4 39 M 7 38.03 27.03 15.38 11.70 22
M 4 19.7 20.4 26.7 18.2 29 M 8 23.36 21.16 24.20 25.71 27
5 29 9 25
WILD-TYPE
M 19.3 8.1 16.2 15.0 M 18.38 9.60 12.54 15.47
mean 21.4 17.5 22.9 20.9 37.6 M 10 28.89 36.39 28.99 30.48 40
SD 2.4 6.7 4.1 6.4 12.6 mean 26.12 22.13 19.03 19.82 29.20
Geomean 21.27 16.31 22.58 14.64 36.17 SD 7.66 10.22 7.18 7.90 7.05
geomean 25.29 20.11 18.03 18.61 28.56
Day of treatment DICLOFENAC 20 mg/kg DICLOFENAC 30 mg/kg
Day -1 Day 2 Day 4 Day 8 Day 8 Auto Day -1 Day 2 Day 4 Day 8
Day 8 
Auto
M 11 23.87 15.03 22.10 20.33 28 M 16 38.51 31.95 31.95 30.32 34
M 12 21.92 21.92 21.92 34.20 42 M 17 33.59 30.32 33.59 27.04 28
M 13 22.10 18.56 18.56 13.26 24 M 18 33.59 27.04 27.04 41.79 46
M 14 27.18 16.66 13.15 18.41 20 M 19 22.12 20.48 20.48 25.40 26
M 15 27.18 21.92 27.18 34.20 36 M 20 33.59 20.48 22.12 38.51 33
mean 24.5 18.8 20.6 24.1 30.0 mean 32.3 26.1 27.0 32.6 33.4
SD 2.6 3.1 5.2 9.6 8.9 SD 6.1 5.4 5.8 7.2 7.8
Geomean 24.34 18.61 20.02 22.53 28.95 Geomean 31.76 25.60 26.53 31.99 32.73
FENCLOZIC ACID (50MG/KG) FENCLOZIC ACID 100 mg/kg
Day -1 Day 2 Day 4 Day 8 Day 8 auto Day -1 Day 2 Day 4 Day 8
Day 8 
Auto
M 21 14.12 18.68 16.37 20.72 41 M 26 23.68 27.18 32.44 51.74 54
M 22 15.71 21.05 20.33 20.26 40 M 27 25.43 28.94 32.44 39.46 46
M 23 14.05 15.64 19.28 20.72 42 M 28 16.66 21.92 30.69 92.07 100
M 24 19.40 21.20 21.63 15.58 31 M 29 20.33 27.40 39.78 69.84 88
M 25 20.49 21.92 22.64 33.61 51 M 30 34.20 39.46 35.95 35.95 44
mean 16.75 19.70 20.05 22.18 41.00 mean 24.06 28.98 34.26 57.81 66.40
SD 3.01 2.58 2.42 6.75 7.11 SD 6.59 6.43 3.63 23.29 25.82
geomean 16.54 19.55 19.93 21.46 40.50 geomean 23.37 28.45 34.11 54.30 62.61
CONTROL fenclozic acid 100mg/Kg
Day -1 Day 2 Day 4 Day 8 Day 8 Auto Day of treatment Day -1 Day 2 Day 4 Day 8
Day 8 
Auto
M 31 1817.1 2461.8 2754.9 1172.3 868 M 40 487.19281 1004.835 1370.23 274.046 276
HRN MICE
M 32 646.0 1409.5 1761.8 3934.8 2900 M 41 213.14685 578.5415 578.5415 1004.835 1562
M 33 830.2 889.5 1186.0 2312.7 1862 M 42 578.54146 548.0919 304.4955 1644.276 2790
M 34 237.2 1067.4 1363.9 1719.7 1426 M 43 424.59701 606.5672 727.8806 272.9552 382
mean 882.6 1457.1 1766.7 2284.9 1764.0 M 44 1243.4627 1182.806 1213.134 515.5821 648
SD 670.5 703.8 701.4 1194.5 859.7 mean 589.4 784.2 838.9 742.3 1131.6
Geomean 693.39 1347.25 1673.92 2069.58 1607.88 SD 389.6 290.3 443.9 586.0 1056.3
Geomean 501.49 744.41 734.07 576.58 784.81
DICLOFENAC 30 mg/kg
Day -1 Day 2 Day 4 Day 8 Day 8 Auto
M 35 357.7822 715.5644 1355.005 639.4406 910
M 36 395.8442 190.3097 1119.021 943.9361 242
M 37 662.2777 266.4336 677.5025 1324.555 284
M 38 553.4925 204.7164 856.7761 1046.328 178
M 39 606.5672 894.6866 614.1493 166.806 188
mean 515.2 454.3 924.5 824.2 360.4
SD 132.7 327.7 310.3 441.7 310.2
Geomean 500.77 366.86 884.23 769.6 353.2
APPENDIX 16
BIOCHEMICAL PARAMETERS IN WILD-TYPE AND HRN MICE
C57BL6J Control
GROUP 1 Animal UREA (mmol/L)
CRE 
(µmol/L)
GLU 
(mmol/L) CHOL (mmol/L)
TG 
(mmol/L) Ca (mmol/L)
TP 
(g/L)
ALB 
(g/L)
GLOB 
(g/L) TBIL
ALP 
(IU/L)
AST 
(IU/L)
ALT 
(IU/L)
GLDH 
(IU/L) BA(µmol/L) HAEM
M 1 0 0 0 0 0 0 0 0 0 4 164 94 59 26 151 1
M 2 0 0 0 0 0 0 0 0 0 1 169 45 32 19 0 1
M 3 0 0 0 0 0 0 0 0 0 2 124 52 39 0 0 1
M 4 0 0 0 0 0 0 0 0 0 1 139 43 29 19 0 -
M 5 0 0 0 0 0 0 0 32 0 1 216 46 29 12 3 -
Mean 0 0 0 0 0 0 0 6.4 0 1.8 162.4 56 37.6 15.2 30.8
SD 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 14.3108 0.0000 1.3038 35.1468 21.5058 12.6412 9.8336 67.2064
geomean #NUM! #NUM! #NUM! #NUM! #NUM! #NUM! #NUM! #NUM! #NUM! 1.19 158.38 46.38 32.01 #NUM! #NUM!
SEM 0.00 15.72 9.62 5.65 4.40 30.06
C57BL6J Diclofenac 10 mg/kg
GROUP 2 Animal UREA (mmol/L)
CRE 
(µmol/L)
GLU 
(mmol/L) CHOL (mmol/L)
TG 
(mmol/L) Ca (mmol/L)
TP 
(g/L)
ALB 
(g/L)
GLOB 
(g/L) TBIL
ALP 
(IU/L)
AST 
(IU/L)
ALT 
(IU/L)
GLDH 
(IU/L) BA(µmol/L) HAEM
M 6 7.7 5 17.8 2.8 2.25 2.73 48 31 17 1 167 42 32 13 2 -
M 7 0 0 16.8 2.5 22 1 80 47 22 9 66 -
M 8 0 0 0 115 40 27 -
M 9 0 0 0 144 40 25 -
M 10 0 0 0 54 40 -
Mean 1.54 1 6.92 2.8 2.25 2.615 48 26.5 17 1 126.5 44.6 29.2 11 34
SD 3.4435 2.2361 9.4822 #DIV/0! #DIV/0! 0.1626 #DIV/0! 6.3640 #DIV/0! 0.0000 37.5988 5.9833 7.0498 2.8284 45.2548
geomean #NUM! #NUM! #NUM! #NUM! #NUM! 2.50 #NUM! 22.00 #NUM! 1.00 109.83 44.89 27.76 9.00 66.00
SEM 18.80 2.68 3.15 2.00 32.00
C57BL6J Diclofenac 20 mg/kg
GROUP 3 animal 
number UREA (mmol/L)
CRE 
(µmol/L)
GLU 
(mmol/L) CHOL (mmol/L)
TG 
(mmol/L) Ca (mmol/L)
TP 
(g/L)
ALB 
(g/L)
GLOB 
(g/L)
ALP 
(IU/L)
AST 
(IU/L)
ALT 
(IU/L)
GLDH 
(IU/L) BA(µmol/L)
M 11 6.4 6 23.4 2.68 1.92 2.52 48.2 32 16.2 132 42 28 14 4
M 12 8.4 6 19 2.52 1.72 2.56 48.2 32 16.2 132 52 42 30 2
M 13 7 6 21.6 2.96 1.46 2.54 45.6 30 15.6 80 30 24 8
M 14 7.6 8 22.2 2.74 1.94 2.66 47.4 30 17.4 86 32 20 12
M 15 7 8 25.4 2.7 1.58 2.52 49 34 15 112 44 36 16 4
Mean 7.28 6.8 22.32 2.72 1.724 2.56 47.68 31.6 16.08 108.4 40 30 16 3.33333333
SD 0.7563 1.0954 2.3563 0.1581 0.2095 0.0583 1.2931 1.6733 0.8899 24.6739 9.0554 8.9443 8.3666 1.1547
geomean 7.25 6.73 22.22 2.72 1.71 2.56 47.67 31.56 16.06 106.07 39.17 28.95 14.52 3.17
SEM 0.34 0.49 1.05 0.07 0.09 0.03 0.58 0.75 0.40 11.03 4.05 4.00 3.74 0.67
C57BL6J Diclofenac 30mg/kg
GROUP 4 Animal UREA (mmol/L)
CRE 
(µmol/L)
GLU 
(mmol/L) CHOL (mmol/L)
TG 
(mmol/L) Ca (mmol/L)
TP 
(g/L)
ALB 
(g/L)
GLOB 
(g/L) TBIL
ALP 
(IU/L)
AST 
(IU/L)
ALT 
(IU/L)
GLDH 
(IU/L) BA(µmol/L)
M 16 6.8 6 22.4 2.9 2.06 2.62 47.6 30 17.6 0 78 44 34 12 0
M 17 17 6 13 2.82 1.2 2.46 44.2 28 16.2 2 48 68 28 12 2
M 18 9.2 6 21 2.86 3.08 2.62 46 28 18 0 84 56 46 14 2
M 19 7.8 6 16.8 2.44 2.06 2.54 43.6 28 15.6 0 80 32 26 8 0
M 20 6.9 9 15.9 2.64 1.44 2.13 43.8 27 16.8 0 78 51 33 15 9
Mean 9.54 6.6 17.82 2.732 1.968 2.474 45.04 28.2 16.84 0.4 73.6 50.2 33.4 12.2 2.6
SD 4.2800 1.3416 3.8421 0.1911 0.7284 0.2034 1.7170 1.0954 0.9839 0.8944 14.5190 13.4239 7.7974 2.6833 3.7148
geomean 9.58 6.64 16.43 2.68 1.82 2.43 44.39 27.75 16.63 #NUM! 70.82 49.93 32.42 11.93 #NUM!
SEM 1.91 0.60 1.72 0.09 0.33 0.09 0.77 0.49 0.44 0.40 6.49 6.00 3.49 1.20 1.66
C57BL6J Fenclozic acid 50 mg/kg
GROUP 5
Animal UREA (mmol/L)
CRE 
(µmol/L)
GLU 
(mmol/L) CHOL (mmol/L)
TG 
(mmol/L) Ca (mmol/L)
TP 
(g/L)
ALB 
(g/L)
GLOB 
(g/L) TBIL
ALP 
(IU/L)
AST 
(IU/L)
ALT 
(IU/L)
GLDH 
(IU/L) BA(µmol/L)
M 21 8.9 0 20.9 2.37 1.88 2.96 55.8 36 19.8 1 176 55 41 9 2 1
M 22 11.7 10 27.3 2.18 1.69 2.92 52 34 18 1 127 44 40 12 4 -
M 23 0 0 0 0 0 0 0 0 0 1 133 48 42 0 0 -
M 24 0 0 0 0 0 0 0 0 0 1 112 37 31 0 0 -
M 25 0 0 0 0 0 0 0 0 0 1 133 61 51 0 0 -
Mean 4.12 2 9.64 0.91 0.714 1.176 21.56 14 7.56 1 136.2 49 41 4.2 1.2
SD 5.7277 4.4721 13.3926 1.2479 0.9800 1.6104 29.5528 19.1833 10.3715 0.0000 23.8474 9.3541 7.1063 5.8481 1.7889
geomean #NUM! #NUM! #NUM! #NUM! #NUM! #NUM! #NUM! #NUM! #NUM! 1.00 125.95 46.73 40.37 #NUM! #NUM!
APPENDIX 16
BIOCHEMICAL PARAMETERS IN WILD-TYPE AND HRN MICE
SEM 2.56 2.00 5.99 0.56 0.44 0.72 13.22 8.58 4.64 0.00 10.66 4.18 3.18 2.62 0.80
Fenclozic acid 100 mg/kg
GROUP 6 animal 
number UREA (mmol/L)
CRE 
(µmol/L)
GLU 
(mmol/L) CHOL (mmol/L)
TG 
(mmol/L) Ca (mmol/L)
TP 
(g/L)
ALB 
(g/L)
GLOB 
(g/L)
ALP 
(IU/L)
AST 
(IU/L)
ALT 
(IU/L)
GLDH 
(IU/L) BA(µmol/L)
M 26 9 10 18.8 1.74 1.88 2.6 47 34 13 122 80 54 14 6
M 27 8.4 10 18.4 1.98 1.62 2.6 48.8 34 14.8 98 54 46 14 10
M 28 7.8 12 20.6 2.44 1.74 2.58 47.4 32 15.4 162 104 100 26 6
M 29 9 10 20.6 2 1.8 2.5 49.8 34 15.8 116 70 88 14 4
M 30 7.4 10 22.2 1.94 1.56 2.58 47.6 34 13.6 142 48 44 16 4
Mean 8.32 10.4 20.12 2.02 1.72 2.572 48.12 33.6 14.52 128 71.2 66.4 16.8 6
SD 0.7155 0.8944 1.5401 0.2565 0.1304 0.0415 1.1541 0.8944 1.1883 24.6577 22.2980 25.8225 5.2154 2.4495
geomean 8.13 10.47 20.40 2.08 1.68 2.56 48.39 33.49 14.88 127.17 65.91 64.96 16.90 5.57
SEM 0.32 0.40 0.69 0.11 0.06 0.02 0.52 0.40 0.53 11.03 9.97 11.55 2.33 1.10
HRN Control
GROUP 7 Animal UREA (mmol/L) CRE (µmol/L)
GLU 
(mmol/L) CHOL (mmol/L)
TG 
(mmol/L) Ca (mmol/L)
TP 
(g/L)
ALB 
(g/L)
GLOB 
(g/L) TBIL
ALP 
(IU/L)
AST 
(IU/L)
ALT 
(IU/L)
GLDH 
(IU/L) BA(µmol/L)
M 31 9.8 8 18.6 1.76 1.16 3.06 60 36 24 6 374 452 868 218 8
M 32 9.4 10 15.8 2.38 0.94 3.1 59.6 36 23.6 14 546 2004 2900 990 18
M 33 10.8 10 16.6 1.4 0.6 2.9 51.2 32 19.2 20 432 1258 1862 492 12
M 34 7.2 8 19.4 1.58 0.64 2.8 52.8 32 20.8 24 424 898 1426 386 12
Mean 9.3 9 17.6 1.78 0.835 2.965 55.9 34 21.9 16 444 1153 1764 521.5 12.5
SD 1.52 1.15 1.68 0.43 0.26 0.14 4.55 2.31 2.29 7.83 72.68 656.16 859.68 332.08 4.12
geomean 9.20 8.94 17.54 1.74 0.80 2.96 55.76 33.94 21.81 14.17 439.77 1005.77 1607.88 449.95 12.00
SEM 0.76 0.58 0.84 0.21 0.13 0.07 2.28 1.15 1.15 3.92 36.34 328.08 429.84 166.04 2.06
HRN Diclofenac 30 mg/kg
GROUP 8 Animal UREA (mmol/L) CRE (µmol/L)
GLU 
(mmol/L) CHOL (mmol/L)
TG 
(mmol/L) Ca (mmol/L)
TP 
(g/L)
ALB 
(g/L)
GLOB 
(g/L) TBIL
ALP 
(IU/L)
AST 
(IU/L)
ALT 
(IU/L)
GLDH 
(IU/L) BA(µmol/L)
M 35 9.8 14 16.8 1.75 1.05 2.52 53.9 35 18.9 7 406 525 910 392 14
M 36 7.8 6 26.6 0.72 0.52 2.78 47.8 28 19.8 2 144 144 242 136 2
M 37 11.2 6 16 0.14 0.46 3.04 48.4 26 22.4 2 116 316 284 172 2
M 38 9.6 6 15.6 0.38 0.66 2.72 47.4 26 21.4 2 90 166 178 92 2
M 39 8.4 2 20.4 0.84 0.74 2.82 47.8 28 19.8 2 126 134 188 66 2
Mean 9.36 6.8 19.08 0.766 0.686 2.776 49.06 28.6 20.46 3 176.4 257 360.4 171.6 4.4
SD 1.3221 4.3818 4.6122 0.6158 0.2317 0.1873 2.7291 3.7148 1.4100 2.2361 129.8260 166.9461 310.2044 129.7413 5.3666
geomean 9.16 4.56 19.18 0.42 0.58 2.84 47.85 26.98 20.82 2.00 117.32 178.37 218.99 109.17 2.00
SEM 0.59 1.96 2.06 0.28 0.10 0.08 1.22 1.66 0.63 1.00 58.06 74.66 138.73 58.02 2.40
HRN Fenclozic acid 100mg/kg
GROUP 9 Animal UREA (mmol/L) CRE (µmol/L)
GLU 
(mmol/L) CHOL (mmol/L)
TG 
(mmol/L) Ca (mmol/L)
TP 
(g/L)
ALB 
(g/L)
GLOB 
(g/L) TBIL
ALP 
(IU/L)
AST 
(IU/L)
ALT 
(IU/L)
GLDH 
(IU/L) BA(µmol/L)
M 40 13 10 20 1.04 2.2 2.88 54.6 34 20.6 2 342 190 276 88 6
M 41 11.2 12 24.4 1.4 0.74 3.1 55.6 34 21.6 8 370 1396 1562 444 10
M 42 7.2 12 23.2 0.86 0.88 2.74 43.8 28 15.8 2 308 2576 2790 150 8
M 43 11.4 8 14.4 1.44 1.1 2.7 49.8 32 17.8 4 318 296 382 100 4
M 44 10 10 28.8 0.98 1.38 2.76 55 34 21 4 290 370 648 90 6
Mean 10.56 10.4 22.16 1.144 1.26 2.836 51.76 32.4 19.36 4 325.6 965.6 1131.6 174.4 6.8
SD 2.1606 1.6733 5.3636 0.2605 0.5784 0.1621 5.0128 2.6077 2.4674 2.4495 31.1256 1022.6548 1056.3327 152.8097 2.2804
geomean 9.79 10.36 22.01 1.14 1.00 2.82 50.82 31.90 18.90 4.00 320.18 792.19 1019.13 156.47 6.62
SEM 0.97 0.75 2.40 0.12 0.26 0.07 2.24 1.17 1.10 1.10 13.92 457.35 472.41 68.34 1.02
APPENDIX 17
STAT ANALYSIS
BIOCHEMICAL PARAMETERS IN WILD-TYPE  
ALKALINE PHOSPHATASE ASSAY
t-Test: Two-Sample Assuming Unequal Variancet-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances
CONTROL Diclofenac 10mg/kg CONTROL diclofenac 20mg/kg CONTROL diclofenac 30mg/kg CONTROL fenclozic acid 50mg/kg CONTROL fenclozic acid 100mg/kg
Mean 162.4 126.5 Mean 162.4 108.4 Mean 162.4 73.6 Mean 162.4 136.2 Mean 162.4 128
Variance 1235.3 1413.667 Variance 1235.3 608.8 Variance 1235.3 210.8 Variance 1235.3 568.7 Variance 1235.3 608
Observation 5 4 Observation 5 5 Observation 5 5 Observation 5 5 Observation 5 5
Hypothesize 0 Hypothesize 0 Hypothesize 0 Hypothesize 0 Hypothesize 0
df 6 df 7 df 5 df 7 df 7
t Stat 1.46503 t Stat 2.811814 t Stat 5.221542 t Stat 1.37933 t Stat 1.791618
P(T<=t) one 0.09663 P(T<=t) one 0.013039 P(T<=t) one 0.001703 P(T<=t) one 0.105124 P(T<=t) one 0.058151
t Critical on 1.94318 t Critical on 1.894579 t Critical on 2.015048 t Critical on 1.894579 t Critical on 1.894579
P(T<=t) two 0.19326 P(T<=t) two 0.026078 P(T<=t) two 0.003406 P(T<=t) two 0.210247 P(T<=t) two 0.116302
t Critical two 2.446912 t Critical two 2.364624 t Critical two 2.570582 t Critical two 2.364624 t Critical two 2.364624
ASPARTATE AMINOTRANSFERASE
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variancet-Test: Two-Sample Assuming Unequal Variances
CONTROL Diclofenac 10mg/kg CONTROL diclofenac 20mg/kg CONTROLofenac 30mg/kg CONTROLozic acid 50mg/kg CONTROLzic acid 100mg/kg
Mean 56 44.6 Mean 56 40 Mean 56 50.2 Mean 56 49 Mean 56 71.2
Variance 462.5 35.8 Variance 462.5 82 Variance 462.5 180.2 Variance 462.5 87.5 Variance 462.5 497.2
Observation 5 5 Observation 5 5 Observation 5 5 Observation 5 5 Observation 5 5
Hypothesize 0 Hypothesize 0 Hypothesize 0 Hypothesize 0 Hypothesize 0
df 5 df 5 df 7 df 5 df 8
t Stat 1.141943 t Stat 1.533226 t Stat 0.511574 t Stat 0.667424 t Stat -1.09714
P(T<=t) one 0.152599 P(T<=t) one 0.092899 P(T<=t) one 0.312343 P(T<=t) one 0.267032 P(T<=t) one 0.152252
t Critical on 2.015048 t Critical on 2.015048 t Critical on 1.894579 t Critical on 2.015048 t Critical on 1.859548
P(T<=t) two 0.305198 P(T<=t) two 0.185798 P(T<=t) two 0.624687 P(T<=t) two 0.534064 P(T<=t) two 0.304504
t Critical two 2.570582 t Critical two 2.570582 t Critical two 2.364624 t Critical two 2.570582 t Critical two 2.306004
ALANINE AMINOTRANSFERASE
t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequal Variancet-Test: Two-Sample Assuming Unequal Variances
CONTROL Diclofenac 10mg/kg CONTROL diclofenac 20mg/kg CONTROL diclofenac 30mg/kg CONTROL fenclozic acid 50mg/kg CONTROL fenclozic acid 100mg/kg
Mean 37.6 29.2 Mean 37.6 30 Mean 37.6 33.4 Mean 37.6 41 Mean 37.6 66.4
Variance 159.8 49.7 Variance 159.8 80 Variance 159.8 60.8 Variance 159.8 50.5 Variance 159.8 666.8
Observation 5 5 Observation 5 5 Observation 5 5 Observation 5 5 Observation 5 5
Hypothesize 0 Hypothesize 0 Hypothesize 0 Hypothesize 0 Hypothesize 0
df 6 df 7 df 7 df 6 df 6
t Stat 1.297694 t Stat 1.097423 t Stat 0.632312 t Stat -0.52426 t Stat -2.23991
P(T<=t) one 0.121023 P(T<=t) one 0.154383 P(T<=t) one 0.273636 P(T<=t) one 0.309447 P(T<=t) one 0.033178
t Critical on 1.94318 t Critical on 1.894579 t Critical on 1.894579 t Critical on 1.94318 t Critical on 1.94318
P(T<=t) two 0.242047 P(T<=t) two 0.308766 P(T<=t) two 0.547272 P(T<=t) two 0.618895 P(T<=t) two 0.066356
t Critical two 2.446912 t Critical two 2.364624 t Critical two 2.364624 t Critical two 2.446912 t Critical two 2.446912
APPENDIX 18 DICLOFENAC
 COVALENT BINDING ASSAY
t‐Test: Two‐Sample Assuming Equal Variances t‐Test: Two‐Sample Assuming Unequal Variances
HRN ‐NADPH, TN +NADPH, T=60 HRN + UDGPA,  + UDGPA, T=60
Mean 10.22435 10.99579 Mean 6.982181 15.96503
Variance 20.01105 35.75078 Variance 20.8217 75.2342
Observatio 3 3 Observatio 3 3
Pooled Var 27.88091 Hypothesiz 0
Hypothesiz 0 df 3
df 4 t Stat ‐1.5875
t Stat ‐0.17893 P(T<=t) one 0.1053
P(T<=t) one 0.433344 t Critical on 2.353363
t Critical on 2 131847 P(T<=t) two 0 2106    .   .
P(T<=t) two 0.866687 t Critical tw 3.182446
t Critical tw 2.776445
t‐Test: Two‐Sample Assuming Equal Variances t‐Test: Two‐Sample Assuming Equal Variances t‐Test: Two‐Sample Assuming Unequal Variances
WT ‐NADPH, T=+ NADPH, T=60 WT + UDPGA, T+ UDPGA, T=60
Mean 9 181171 39 50165 Mean 3 789013 12 7035 WT + NADPH TT + ABT T=60. . . .     ,      , 
Variance 6.753729 103.4711 Variance 0.5512 3.022867 Mean 39.50165 9.887867
Observatio 3 3 Observatio 3 3 Variance 103.4711 15.23517
Pooled Var 55.11244 Pooled Var 1.787034 Observatio 3 3
Hypothesiz 0 Hypothesiz 0 Hypothesiz 0
df 4 df 4 df 3
t Stat ‐5.00215 t Stat ‐8.16725 t Stat 4.707795
P(T<=t) one 0 00374 P(T<=t) one 0 000612 P(T<=t) one 0 00907  .   .   .
t Critical on 2.131847 t Critical on 2.131847 t Critical on 2.353363
P(T<=t) two 0.007479 P(T<=t) two 0.001224 P(T<=t) two 0.018139
t Critical tw 2.776445 t Critical tw 2.776445 t Critical tw 3.182446
t‐Test: Two‐Sample Assuming unqual Varianct‐Test: Two‐Sample Assuming Equal Variances t‐Test: Two‐Sample Assuming Unequal Variances
DOG ‐NADPH, T + NADPH, T=60 DOG + UDPGA,  + UDPGA, T=60 DOG + ABT, T=+ NADPH, T=60
Mean 13.7 64.43896 Mean 7.351351 48.70855 Mean 29.36579 64.43896
Variance 26.71121 176.2395 Variance 8.362312 109.4573 Variance 240.8824 176.2395
Observatio 3 3 Observatio 3 3 Observatio 3 3
Pooled Var 101.4754 Pooled Var 58.90979 Hypothesiz 0
Hypothesiz 0 Hypothesiz 0 df 4
df 4 df 4 t Stat ‐2.97443
t Stat ‐6.16889 t Stat ‐6.59938 P(T<=t) one 0.020482
P(T<=t) one 0.001753 P(T<=t) one 0.001366 t Critical on 2.131847
t Critical on 2.131847 t Critical on 2.131847 P(T<=t) two 0.040964
P(T<=t) two 0.003506 P(T<=t) two 0.002732 t Critical tw 2.776445
t Critical tw 2.776445 t Critical tw 2.776445
APPENDIX 19
STAT ANALYSIS FOR FENCLOZIC ACID COVALENT BINDING
t-Test: Two-Sample Assuming Equal Variances t-Test: Two-Sample Assuming Unequal Variances
HRN -NADPH, HRN +NADPH, T=60 HRN + UDGPA, HRN + UDGPA, T=60
Mean 9.811 32.1451 Mean 8.14701 9.15243
Variance3.14231 54.4088 Variance0.43895 8.30497
Observat 3 3 Observat 3 3
Pooled V28.7756 Hypothes 0
Hypothes 0 df 2
df 4 t Stat -0.5889
t Stat -5.0992 P(T<=t) 0.30779
P(T<=t) 0.00349 t Critic2.91999
t Critic2.13185 P(T<=t) 0.61557
P(T<=t) 0.00699 t Critic4.30265
t Critic2.77645
t-Test: Two-Sample Assuming Unequal Variances
t-Test: Two-Sample Assuming Unequal Vart-Test: Two-Sample Assuming Unequal Variances
WT -NADPH, T WT + NADPH, T=60
Mean 9.66728 187.729 WT + NADPH, WT + ABT, T=60 WT + UDPGA, WT + UDPGA, T=60
Variance0.18253 887.133 Mean 187.729 39.5365 Mean 7.10392 10.4086
Observat 3 3 Variance887.133 111.414 Variance 3.4093 3.89826
Hypothes 0 Observat 3 3 Observat 3 3
df 2 Hypothes 0 Hypothes 0
t Stat -10.354 df 2 df 4
P(T<=t) 0.0046 t Stat 8.12272 t Stat -2.1174
t Critic2.91999 P(T<=t) 0.00741 P(T<=t) 0.05082
P(T<=t) 0.0092 t Critic2.91999 t Critic2.13185
t Critic4.30265 P(T<=t) 0.01482 P(T<=t) 0.10164
t Critic4.30265 t Critic2.77645
t-Test: Two-Sample Assuming Unet-Test: Two-Sample Assuming Unet-Test: Two-Sample Assuming Unequal Variances
DOG -NADPH, DOG + NADPH, T=60DOG + NADPH, DOG + ABT, T=60 DOG + UDPGA, DOG + UDPGA, T=60
Mean 11.5082 67.0877 Mean 67.0877 34.492 Mean 8.49722 15.0356
Variance36.6418 207.242 Variance207.242 1.3154 Variance1.17504 19.7186
Observat 3 3 Observat 3 3 Observat 3 3
Hypothes 0 Hypothes 0 Hypothes 0
df 3 df 2 df 2
t Stat 6 1643 t Stat 3 90938 t Stat 2 4776 - .  .  - .
P(T<=t) 0.0043 P(T<=t) 0.02982 P(T<=t) 0.06576
t Critic2.35336 t Critic2.91999 t Critic2.91999
P(T<=t) 0.00859 P(T<=t) 0.05964 P(T<=t) 0.13152
t Critic3.18245 t Critic4.30265 t Critic4.30265
APPENDIX 20
LIVER-TO-BODY-WEIGHT RATIO 
IN WILD-TYPE AND HRN MICE
t-Test: Two-Sample Assuming Unequal Varian t-Test: Two-Sample Assuming Unequal Varian t-Test: Two-Sample Assuming Unequal Varian t-Test: Two-Sample Assuming Unequal Varian t-Test: Two-Sample Assuming Unequal Varian
CONTROL DFC 10mg/kg CONTROL FC 20mg/kg CONTROL FC 30mg/kg CONTROL A 50 mg/kg CONTROLA 100 mg/kg
Mean 0.05589 0.06113 Mean 0.05589 0.06594 Mean 0.05589 0.06255 Mean 0.05589 0.05873 Mean 0.05589 0.06797
Variance 6.1E-05 3.3E-05 Variance 6.1E-05 7.4E-06 Variance 6.1E-05 3.5E-05 Variance 6.1E-05 3.3E-06 Variance 6.1E-05 2.2E-05
Observat 5 5 Observat 5 5 Observat 5 5 Observat 5 5 Observat 5 4
H th 0 H th 0 H th 0 H th 0 H th 0
WILD-TYPE
ypo es ypo es ypo es ypo es ypo es
df 7 df 5 df 7 df 4 df 7
t Stat -1.2098 t Stat -2.718 t Stat -1.5221 t Stat -0.794 t Stat -2.88
P(T<=t) 0.13281 P(T<=t) 0.02094 P(T<=t) 0.0859 P(T<=t) 0.23581 P(T<=t) 0.01183
t Critic 1.89458 t Critic 2.01505 t Critic 1.89458 t Critic 2.13185 t Critic 1.89458
P(T<=t) 0.26562 P(T<=t) 0.04188 P(T<=t) 0.1718 P(T<=t) 0.47162 P(T<=t) 0.02365
t Critic 2.36462 t Critic 2.57058 t Critic 2.36462 t Critic 2.77645 t Critic 2.36462
t-Test: Two-Sample Assuming Equal Variance t-Test: Two-Sample Assuming Equal Variances
CONTROL FC 30mg/kg CONTROLA 100 mg/kg
Mean 0.10809 0.10765 Mean 0.10809 0.11273
HRN
Variance 2.7E-05 9.1E-05 Variance 2.7E-05 3.5E-05
Observat 4 5 Observat 4 5
Pooled V 6.4E-05 Pooled V 3.2E-05
Hypothes 0 Hypothes 0
df 7 df 7
t Stat 0.08141 t Stat -1.2288
P(T<=t) 0.4687 P(T<=t) 0.12942
t Critic 1.89458 t Critic 1.89458
P(T<=t) 0 93739 P(T<=t) 0 25884 .  .
t Critic 2.36462 t Critic 2.36462
APPENDIX 21
STAT FOR CLINICAL CHEMISTRY DATA HRN MICE
t-Test: Two-Sample Assuming Unequat-Test: Two-Sample Assuming Unequal Varian t-Test: Two-Sample Assuming Unequat-Test: Two-Sample Assuming Unequal Variances
t-Test: Two-Sample Assuming Unequat-Test: Two-Sample Assuming Unequal Varian
CONTROL DFC 30 mg/kg CONTROL FA 100 mg/kg CONTROL DFC 30 mg/kg CONTROL FA 100 mg/kg
UREA CREATINE
TRIGLYCERIDES
Mean 9.3 9.36 Mean 9.3 10.56 Mean 9 6.8 Mean 9 10.4 CONTROLFC 30 mg/kg CONTROLA 100 mg/kg
Variance 2.30667 1.748 Variance 2.30667 4.668 Variance 1.33333 19.2 Variance 1.33333 2.8 Mean 0.835 0.686 Mean 0.835 1.26
Observat 4 5 Observat 4 5 Observat 4 5 Observat 4 5 Variance 0.06997 0.05368 Variance 0.06997 0.3346
Hypothes 0 Hypothes 0 Hypothes 0 Hypothes 0 Observat 4 5 Observat 4 5
df 6 df 7 df 5 df 7 Hypothes 0 Hypothes 0
t Stat -0.0623 t Stat -1.0253 t Stat 1.07691 t Stat -1.4812 df 6 df 6
P(T<=t) 0.47616 P(T<=t) 0.16967 P(T<=t) 0.16536 P(T<=t) 0.09105 t Stat 0.88685 t Stat -1.4628
t Critic 1.94318 t Critic 1.89458 t Critic 2.01505 t Critic 1.89458 P(T<=t) 0.20465 P(T<=t) 0.09692
P(T<=t) 0.95232 P(T<=t) 0.33935 P(T<=t) 0.33071 P(T<=t) 0.1821 t Critic 1.94318 t Critic 1.94318
t Critic 2.44691 t Critic 2.36462 t Critic 2.57058 t Critic 2.36462 P(T<=t) 0.4093 P(T<=t) 0.19384
t Critic 2.44691 t Critic 2.44691
t-Test: Two-Sample Assuming Unequat-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequat-Test: Two-Sample Assuming Unequal Varian t-Test: Two-Sample Assuming Unequat-Test: Two-Sample Assuming Unequal Varian
CONTROL DFC 30 mg/kg CONTROLA 100 mg/kg CONTROLFC 30 mg/kg CONTROLA 100 mg/kg CONTROLFC 30 mg/kg CONTROLA 100 mg/kg
Mean 17.6 19.08 Mean 17.6 22.16 Mean 1.78 0.766 Mean 1.78 1.144 Mean 55.9 49.06 Mean 55.9 51.76
Variance 2.82667 21.272 Variance 2.82667 28.768 Variance 0.1816 0.37918 Variance 0.1816 0.06788 Variance 20.7333 7.448 Variance 20.7333 25.128
Ob t 4 5 Ob t 4 5 Ob t 4 5 Ob t 4 5 Ob t 4 5 Ob t 4 5
TOTAL PROTEINGLUCOSE CHOLESTEROL
serva serva serva serva serva serva
Hypothes 0 Hypothes 0 Hypothes 0 Hypothes 0 Hypothes 0 Hypothes 0
df 5 df 5 df 7 df 5 df 5 df 7
t Stat -0.6645 t Stat -1.7941 t Stat 2.91221 t Stat 2.6189 t Stat 2.64788 t Stat 1.29572
P(T<=t) 0.2679 P(T<=t) 0.06638 P(T<=t) 0.01129 P(T<=t) 0.02358 P(T<=t) 0.02277 P(T<=t) 0.11808
t Critic 2.01505 t Critic 2.01505 t Critic 1.89458 t Critic 2.01505 t Critic 2.01505 t Critic 1.89458
P(T<=t) 0.5358 P(T<=t) 0.13277 P(T<=t) 0.02259 P(T<=t) 0.04716 P(T<=t) 0.04554 P(T<=t) 0.23616
t Critic 2.57058 t Critic 2.57058 t Critic 2.36462 t Critic 2.57058 t Critic 2.57058 t Critic 2.36462
GLOBULIN TOTAL BILIRUBIN
t-Test: Two-Sample Assuming Unequat-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequat-Test: Two-Sample Assuming Unequal Variances ALANINE AMINOTRANSFERASE
t-Test: Two-Sample Assuming Unequat-Test: Two-Sample Assuming Unequa
CONTROL DFC 30 mg/kg CONTROL FA 100 mg/kg CONTROL DFC 30 mg/kg CONTROL FA 100 mg/kg
Mean 21.9 20.46 Mean 21.9 19.36 Mean 16 3 Mean 16 4 CONTROL DFC 30 mg/kg CONTROLA 100 mg/kg
Variance 5.26667 1.988 Variance 5.26667 6.088 Variance 61.3333 5 Variance 61.3333 6 Mean 1764 360.4 Mean 1764 1131.6
Observat 4 5 Observat 4 5 Observat 4 5 Observat 4 5 Variance 739053 96226.8 Variance 739053 1115839
Hypothes 0 Hypothes 0 Hypothes 0 Hypothes 0 Observat 4 5 Observat 4 5
df 5 df 7 df 3 df 3 Hypothes 0 Hypothes 0
t Stat 1.09982 t Stat 1.59554 t Stat 3.21667 t Stat 2.95122 df 4 df 7    
P(T<=t) 0.16076 P(T<=t) 0.07731 P(T<=t) 0.02435 P(T<=t) 0.02998 t Stat 3.10756 t Stat 0.99014
t Critic 2.01505 t Critic 1.89458 t Critic 2.35336 t Critic 2.35336 P(T<=t) 0.01798 P(T<=t) 0.17754
P(T<=t) 0.32152 P(T<=t) 0.15462 P(T<=t) 0.04871 P(T<=t) 0.05997 t Critic 2.13185 t Critic 1.89458
t Critic 2.57058 t Critic 2.36462 t Critic 3.18245 t Critic 3.18245 P(T<=t) 0.03596 P(T<=t) 0.35509
t Critic 2.77645 t Critic 2.36462
BILE ACID
t-Test: Two-Sample Assuming Unequat-Test: Two-Sample Assuming Unequal Variances t-Test: Two-Sample Assuming Unequat-Test: Two-Sample Assuming Unequal Varian t-Test: Two-Sample Assuming Unequat-Test: Two-Sample Assuming Unequal Varian
ALKALINE PHOSPHATASE ASPARTATE AMINOTRANSFERASE
CONTROL DFC 30 mg/kg CONTROL FA 100 mg/kg CONTROL DFC 30 mg/kg CONTROL FA 100 mg/kg CONTROLFC 30 mg/kg CONTROLA 100 mg/kg
Mean 444 176.4 Mean 444 325.6 Mean 1153 257 Mean 1153 965.6 Mean 12.5 4.4 Mean 12.5 6.8
Variance 5282.67 16854.8 Variance 5282.67 968.8 Variance 430551 27871 Variance 430551 1045823 Variance 17 28.8 Variance 17 5.2
Observat 4 5 Observat 4 5 Observat 4 5 Observat 4 5 Observat 4 5 Observat 4 5
Hypothes 0 Hypothes 0 Hypothes 0 Hypothes 0 Hypothes 0 Hypothes 0
df 6 df 4 df 3 df 7 df 7 df 4
t Stat 3.90683 t Stat 3.04248 t Stat 2.66294 t Stat 0.33295 t Stat 2.56017 t Stat 2.47826
P(T<=t) 0.00396 P(T<=t) 0.01915 P(T<=t) 0.03807 P(T<=t) 0.37446 P(T<=t) 0.01877 P(T<=t) 0.03417
t Critic 1.94318 t Critic 2.13185 t Critic 2.35336 t Critic 1.89458 t Critic 1.89458 t Critic 2.13185
P(T<=t) 0.00792 P(T<=t) 0.03831 P(T<=t) 0.07615 P(T<=t) 0.74892 P(T<=t) 0.03754 P(T<=t) 0.06834
t Critic 2.44691 t Critic 2.77645 t Critic 3.18245 t Critic 2.36462 t Critic 2.36462 t Critic 2.77645
APPENDIX 21
STAT FOR CLINICAL CHEMISTRY DATA HRN MICE
ces t-Test: Two-Sample Assuming Uneqt-Test: Two-Sample Assuming Unequal Variances
CONTROLFC 30 mg/kg CONTROLA 100 mg/kg
Mean 2.965 2.776 Mean 2.965 2.836
Variance 0 01957 0 03508 Variance 0 01957 0 02628
CALCIUM
. . . .
Observat 4 5 Observat 4 5
Hypothes 0 Hypothes 0
df 7 df 7
t Stat 1.732 t Stat 1.28058
P(T<=t) 0.06344 P(T<=t) 0.12057
t Critic 1.89458 t Critic 1.89458
P(T<=t) 0.12688 P(T<=t) 0.24114
t Critic 2.36462 t Critic 2.36462
ces t-Test: Two-Sample Assuming Uneqt-Test: Two-Sample Assuming Unequal Variances
CONTROLFC 30 mg/kg CONTROLA 100 mg/kg
Mean 34 28.6 Mean 34 32.4
Variance 5.33333 13.8 Variance 5.33333 6.8
Observat 4 5 Observat 4 5
Hypothes 0 Hypothes 0
df 7 df 7
ALBUMIN
t Stat 2.66904 t Stat 0.97493
P(T<=t) 0.01602 P(T<=t) 0.18104
t Critic 1.89458 t Critic 1.89458
P(T<=t) 0.03204 P(T<=t) 0.36207
t Critic 2.36462 t Critic 2.36462
GLUTAMATE DEHYDROGENASE
al Variances t-Test: Two-Sample Assuming Uneqt-Test: Two-Sample Assuming Unequal Variances        
CONTROLC 30 mg/kg CONTROLA 100 mg/kg
Mean 521.5 171.6 Mean 521.5 174.4
Variance 110278 16833 Variance 110278 23350.8
Observat 4 5 Observat 4 5
Hypothes 0 Hypothes 0
df 4 df 4
t Stat 1.98935 t Stat 1.93312
P(T<=t) 0.05877 P(T<=t) 0.06268
t Critic 2.13185 t Critic 2.13185
P(T<=t) 0.11754 P(T<=t) 0.12536
t Critic 2.77645 t Critic 2.77645
ces
